

HEALTH ANNUAL STATEMENT

FOR THE YEAR ENDED DECEMBER 31, 2015 OF THE CONDITION AND AFFAIRS OF THE

HealthSpring Life & Health Insurance Company, Inc.

Organized under the Laws of Country of Domicile United States of America Licensed as business type: Life, Accident & Health Is HMO Federally Qualified? Yes [] No [X] Incorporated/Organized 0227/2007 Commenced Business 0227/2007 Statutory Home Office 2900 North Loop West, Suite 1300 Houston, TX, US 77092 (Street and Number) (City or Town, State, Country and Zip Code) Main Administrative Office Nashville , TN, US 37228 (City or Town, State, Country and Zip Code) (Street and Number) (City or Town, State, Country and Zip Code) Mail Address 530 Great Circle Road (Street and Number) (City or Town, State, Country and Zip Code) Mail Address 530 Great Circle Road (Street and Number) (City or Town, State, Country and Zip Code) Mail Address 530 Great Circle Road (Street and Number) (City or Town, State, Country and Zip Code) Primary Location of Books and Records S30 Great Circle Road (Street and Number) (City or Town, State, Country and Zip Code) Primary Location of Books and Records (Street and Number) (Street and Number) (Street and Number) Mail Address S30 Great Circle Road (Street and Number) (Area Code) (Telephone Number) Internet Website Address www.cignahealthspring.com (FAX Number) President, Chairman & (Name) (E-mail Address) OFFICERS President, Chairman & Matthew Shawn Morris Vice President & Secretary (FAX Number) OFFICERS President, Chairman & Allen Curis Perez, Vice President & Secretary David Bradity Foliaday, President Covernme Pharmacy Services (Freasure) Freasurer (FResurer Rausener Haumen) Fresident (Freasurer FResurer FRES	
Life, Accident & Health Is HMO Federally Qualified? Yes [] No [X] Incorporated/Organized	
Is HMO Federally Qualified? Yes [] No [X] Incorporated/Organized	
Statutory Home Office 2900 North Loop West, Suite 1300 Houston, TX, US 77092	
Statutory Home Office 2900 North Loop West, Suite 1300 (City or Town, State, Country and Zip Code) Main Administrative Office 530 Great Circle Road (Street and Number) 615-291-7000 (City or Town, State, Country and Zip Code) (Area Code) (Telephone Number) Mail Address 530 Great Circle Road (Street and Number) 615-291-7000 (City or Town, State, Country and Zip Code) (Area Code) (Telephone Number) Mail Address 530 Great Circle Road (Street and Number or P.O. Box) (City or Town, State, Country and Zip Code) Primary Location of Books and Records 530 Great Circle Road (Street and Number) Nashville , TN, US 37228 (Street and Number) (City or Town, State, Country and Zip Code) (Area Code) (Telephone Number) Internet Website Address www.cignahealthspring.com Statutory Statement Contact Beth Ann Hollingsworth (Name) (Area Code) (Telephone Number) (FAX Number) OFFICERS President, Chairman & Chief Executive Officer Matthew Shawn Morris Vice President & Secretary Chief Financial Officer Ryan Bruce McGroarty Corporate Medical Director Dirk Oliver Wales MD Sheffield Hoover Young #, Divisional President Allen Curtis Perez, Vice President Allen Appel, Compiliance Officer Gregory Nicholas Malone, Appointed Addresy Scott Ronald Lambert, Vice President Treasurer Kevin James Oleksak, Assistant Secretary Scott Ronald Lambert, Vice President Secretary Scott Ronald Lambert, Vice President Treasurer Kevin James Oleksak, Assistant Secretary Scott Ronald Lambert, Vice President Treasurer Kevin James Oleksak, Assistant Secretary Scott Ronald Lambert, Vice President Secretary Scott Ronald Lambert, Vice President Treasurer Kevin James Oleksak, Assistant Secretary Scott Ronald Lambert, Vice President Treasurer Kevin James Oleksak, Assistant Secretary Scott Ronald Lamber, Vice President Treasurer Kevin James Oleksak, Assistant Secretary Scott Ronald Lamber, Vice President Treasurer Scott Ron	
(Street and Number) (City or Town, State, Country and Zip Code) Main Administrative Office S30 Great Circle Road (Street and Number) 615-291-7000	
Main Administrative Office Nashville TN, US 37228 Street and Number) G15-291-7000	
Street and Number City or Town, State, Country and Zip Code	
Nashville , TN, US 37228 615-291-7000	
Mail Address 530 Great Circle Road (Street and Number or P.O. Box) (City or Town, State, Country and Zip Code) Primary Location of Books and Records 530 Great Circle Road (Street and Number) Nashville , TN, US 37228 (Street and Number) (City or Town, State, Country and Zip Code) (Area Code) (Telephone Number) Internet Website Address www.cignahealthspring.com Statutory Statement Contact Beth Ann Hollingsworth (Name) (Area Code) (Telephone Number) regulatory@healthspring.com (E-mail Address) (FAX Number) OFFICERS President, Chairman & Chee Executive Officer Matthew Shawn Morris Vice President & Secretary (FAX Number) Sheffield Hoover Young #, Divisional President Allen Curtis Perez, Vice President (David Bradley Holladay, President, Government Richard Alan Appel, Compilance Officer Gregory Nicholas Malone, Appointed Actuary Maureen Hardinan Ryan, Vice President & Assistant Treasurer Kevin James Oleksak, Assistant Secretary Jumana Nadeem Siddiqui, Assistant Treasurer Kevin James Oleksak, Assistant Secretary Jumana Nadeem Siddiqui, Assistant Treasurer Kevin James Oleksak, Assistant Secretary Jumana Nadeem Siddiqui, Assistant Treasurer	
City or Town, State, Country and Zip Code	
Primary Location of Books and Records Nashville	
(Street and Number) (City or Town, State, Country and Zip Code) (City or Town, State, Country and Zip Code) (City or Town, State, Country and Zip Code) (Area Code) (Telephone Number) (FAX Number) (FAX Number) OFFICERS President, Chairman & Matthew Shawn Morris Chief Executive Officer Ryan Bruce McGroarty Corporate Medical Director OTHER Sheffield Hoover Young #, Divisional President Allen Curtis Perez, Vice President Richard Alan Appel, Compliance Officer Ryan, Vice President & Allen Curtis Perez, Vice President Richard Alan Appel, Compliance Officer Maureen Hardiman Ryan, Vice President & Assistant Treasurer Jumana Nadeem Siddiqui, Assistant Treasurer Kevin James Oleksak, Assistant Secretary	
Internet Website Address	
Statutory Statement Contact Beth Ann Hollingsworth (Name) (Area Code) (Telephone Number) (615-401-4566 (FAX Number) (FAX Number) (FAX Number) Ce-mail Address)	
Statutory Statement Contact Beth Ann Hollingsworth (Name) (Area Code) (Telephone Number) (615-401-4566 (FAX Number) (FAX Number) (FAX Number) Ce-mail Address)	
(Name) (Area Code) (Telephone Number) regulatory@healthspring.com , 615-401-4566 (E-mail Address) (FAX Number) OFFICERS President, Chairman & Chief Executive Officer Matthew Shawn Morris Vice President & Secretary Brent Jason Sanders # Chief Financial Officer Ryan Bruce McGroarty Corporate Medical Director Dirk Oliver Wales MD OTHER Sheffield Hoover Young #, Divisional President Jay Landon Hurt, Divisional President Peter Ronald Gardner, Vice President Kristinn Klunkert Benton, Vice President Allen Curtis Perez, Vice President David Bradley Holladay, President, Government Pharmcacy Services Richard Alan Appel, Compliance Officer Gregory Nicholas Malone, Appointed Actuary Maureen Hardiman Ryan, Vice President & Assistant Treasurer Jumana Nadeem Siddiqui, Assistant Treasurer Kevin James Oleksak, Assistant Secretary	
(E-mail Address) OFFICERS President, Chairman & Chief Executive Officer Matthew Shawn Morris Vice President & Secretary Brent Jason Sanders # Chief Financial Officer Ryan Bruce McGroarty Corporate Medical Director Dirk Oliver Wales MD OTHER Sheffield Hoover Young #, Divisional President Jay Landon Hurt, Divisional President Peter Ronald Gardner, Vice President Kristinn Klunkert Benton, Vice President Allen Curtis Perez, Vice President David Bradley Holladay, President, Government Pharmacy Services Richard Alan Appel, Compliance Officer Gregory Nicholas Malone, Appointed Actuary Maureen Hardiman Ryan, Vice President & Assistant Treasurer Jumana Nadeem Siddiqui, Assistant Treasurer Kevin James Oleksak, Assistant Secretary	
President, Chairman & Chief Executive Officer Matthew Shawn Morris Vice President & Secretary Brent Jason Sanders # Chief Financial Officer Ryan Bruce McGroarty Corporate Medical Director Dirk Oliver Wales MD OTHER Sheffield Hoover Young #, Divisional President Jay Landon Hurt, Divisional President David Bradley Holladay, President, Government Allen Curtis Perez, Vice President Pharmcacy Services Richard Alan Appel, Compliance Officer Gregory Nicholas Malone, Appointed Actuary Maureen Hardiman Ryan, Vice President & Assistant Treasurer Kevin James Oleksak, Assistant Secretary Matthew Shawn Morris Vice President & Secretary Brent Jason Sanders # Dirk Oliver Wales MD Peter Ronald Gardner, Vice President David Bradley Holladay, President, Government Pharmcacy Services Scott Ronald Lambert, Vice President & Treas	
President, Chairman & Chief Executive Officer Matthew Shawn Morris Vice President & Secretary Brent Jason Sanders # Chief Financial Officer Ryan Bruce McGroarty Corporate Medical Director Dirk Oliver Wales MD OTHER Sheffield Hoover Young #, Divisional President Jay Landon Hurt, Divisional President David Bradley Holladay, President, Government Allen Curtis Perez, Vice President Pharmcacy Services Richard Alan Appel, Compliance Officer Gregory Nicholas Malone, Appointed Actuary Maureen Hardiman Ryan, Vice President & Assistant Treasurer Kevin James Oleksak, Assistant Secretary Matthew Shawn Morris Vice President & Secretary Brent Jason Sanders # Dirk Oliver Wales MD Peter Ronald Gardner, Vice President David Bradley Holladay, President, Government Pharmcacy Services Scott Ronald Lambert, Vice President & Treas	
Chief Financial Officer Ryan Bruce McGroarty Corporate Medical Director Dirk Oliver Wales MD OTHER Sheffield Hoover Young #, Divisional President Jay Landon Hurt, Divisional President David Bradley Holladay, President, Government Michael Allen Curtis Perez, Vice President Pharmacy Services Richard Alan Appel, Compliance Officer Gregory Nicholas Malone, Appointed Actuary Scott Ronald Lambert, Vice President & Treasurer Treasurer Kevin James Oleksak, Assistant Secretary	
Sheffield Hoover Young #, Divisional President By Landon Hurt, Divisional President Allen Curtis Perez, Vice President Bichard Alan Appel, Compliance Officer Maureen Hardiman Ryan, Vice President & Assistant Treasurer Allen Curtis Perez, Vice President Breazing Caregory Nicholas Malone, Appointed Actuary Scott Ronald Lambert, Vice President & Treasurer Kevin James Oleksak, Assistant Secretary	
Sheffield Hoover Young #, Divisional President By Landon Hurt, Divisional President Allen Curtis Perez, Vice President Bichard Alan Appel, Compliance Officer Maureen Hardiman Ryan, Vice President & Assistant Treasurer Allen Curtis Perez, Vice President Breazing Caregory Nicholas Malone, Appointed Actuary Scott Ronald Lambert, Vice President & Treasurer Kevin James Oleksak, Assistant Secretary	
Kristinn Klunkert Benton, Vice President Allen Curtis Perez, Vice President Pharmcacy Services Richard Alan Appel, Compliance Officer Gregory Nicholas Malone, Appointed Actuary Scott Ronald Lambert, Vice President & Treas Maureen Hardiman Ryan, Vice President & Assistant Treasurer Jumana Nadeem Siddiqui, Assistant Treasurer Kevin James Oleksak, Assistant Secretary	- nt
Maureen Hardiman Ryan, Vice President & Assistant Treasurer Jumana Nadeem Siddiqui, Assistant Treasurer Kevin James Oleksak, Assistant Secretary	
	!
·	
DIRECTORS OR TRUSTEES Jay Landon Hurt Brent Jason Sanders # Ryan Bruce McGroarty	
Peter Ronald Gardner Sheffield Hoover Young #	
State of Maryland SS: County of Harford	
The officers of this reporting entity being duly sworn, each depose and say that they are the described officers of said reporting entity, and that on the reporting period stated all of the herein described assets were the absolute property of the said reporting entity, free and clear from any liens or claims thereon, except as herein stated, and	
statement, together with related exhibits, schedules and explanations therein contained, annexed or referred to, is a full and true statement of all the assets and liabilities ar condition and affairs of the said reporting entity as of the reporting period stated above, and of its income and deductions therefrom for the period ended, and have been conditionable.	nd of the
in accordance with the NAIC Annual Statement Instructions and Accounting Practices and Procedures manual except to the extent that: (1) state law may differ; or, (2) th	nat state
rules or regulations require differences in reporting not related to accounting practices and procedures, according to the best of their information, knowledge and respectively. Furthermore, the scope of this attestation by the described officers also includes the related corresponding electronic filing with the NAIC, when required, the	nat is an
exact copy (except for formatting differences due to electronic filing) of the enclosed statement. The electronic filing may be requested by various regulators in lieu of or in to the enclosed statement.	addition
Matthew Shawn Morris Ryan Bruce McGroarty Brent Jason Sanders #	
President, Chairman and Chief Executive Officer Chief Financial Officer Vice President and Secretary	
a. Is this an original filing?	
day of February, 2016 1. State the amendment number	
2. Date filed 3. Number of pages attached	
Christina Y. Schneider Notary Public October 31, 2016	

ASSETS

			Guilelli Teal		FIIUI Teal
		1	2	3 Net Admitted Assets	4 Net Admitted
	D + (0 + + + D)	Assets	Nonadmitted Assets	(Cols. 1 - 2)	Assets
1.	,	303,800,475		303,800,475	273,829,942
2.	Stocks (Schedule D):			0	0
	2.1 Preferred stocks			0	_
0	2.2 Common stocks			0	0
3.	Mortgage loans on real estate (Schedule B): 3.1 First liens			0	0
	3.2 Other than first liens.			0	0
4.	Real estate (Schedule A):				
	4.1 Properties occupied by the company (less \$				0
	encumbrances)			0	0
	4.2 Properties held for the production of income (less				
	\$ encumbrances)			0	0
	4.3 Properties held for sale (less \$				
	encumbrances)			0	0
5.	Cash (\$16, 150, 346 , Schedule E - Part 1), cash equivalents				
	(\$63,403,433 , Schedule E - Part 2) and short-term				
	investments (\$480,787 , Schedule DA)	80,034,566		80,034,566	15,296,468
6.	Contract loans, (including \$0 premium notes)			0	0
7.	Derivatives (Schedule DB)			0	0
8.	Other invested assets (Schedule BA)			0	0
9.	Receivables for securities			0	0
10.	Securities lending reinvested collateral assets (Schedule DL)			0	0
11.	Aggregate write-ins for invested assets	0	0	0	0
12.	Subtotals, cash and invested assets (Lines 1 to 11)	383,835,041	0	383,835,041	289, 126, 410
13.	Title plants less \$0 charged off (for Title insurers				
	only)			0	0
14.	Investment income due and accrued	3,407,175	0	3,407,175	3,214,960
15.	Premiums and considerations:				
	15.1 Uncollected premiums and agents' balances in the course of collection	40,932,230		40,932,230	25,234,192
	15.2 Deferred premiums and agents' balances and installments booked but				
	deferred and not yet due (including \$0				
	earned but unbilled premiums)			0	0
	15.3 Accrued retrospective premiums (\$0) and				
	contracts subject to redetermination (\$0)			0	0
16.	Reinsurance:				
	16.1 Amounts recoverable from reinsurers			0	0
	16.2 Funds held by or deposited with reinsured companies			0	0
	16.3 Other amounts receivable under reinsurance contracts				0
17.	Amounts receivable relating to uninsured plans				
	Current federal and foreign income tax recoverable and interest thereon			2,958,102	
				9,260,076	18,323,989
19.	Guaranty funds receivable or on deposit				
20.	Electronic data processing equipment and software				0
21.	Furniture and equipment, including health care delivery assets				
	(\$			0	0
22.	Net adjustment in assets and liabilities due to foreign exchange rates				0
23.	Receivables from parent, subsidiaries and affiliates				
24.	Health care (\$24,826,014) and other amounts receivable				
25.	Aggregate write-ins for other than invested assets				
26.	Total assets excluding Separate Accounts, Segregated Accounts and				
20.	Protected Cell Accounts (Lines 12 to 25)	622,870,348	8,916,553	613,953,794	586,050,035
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts			0	0
28.	Total (Lines 26 and 27)	622,870,348	8,916,553	613,953,794	586,050,035
20.	DETAILS OF WRITE-INS	022,070,010	3,010,000	310,000,101	000,000,000
1101					
1101. 1102.					
1102. 1103.					
	Summary of remaining write-ins for Line 11 from overflow page				
1198.		0	0	0	00
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)			-	
	Health Insurance Industry Fee Reimbursement	, ,		4,164,724	
	State Income Taxes Recoverable			392,016	528,265
	Provider Pass Thru Payment from State of Texas			216	
	Summary of remaining write-ins for Line 25 from overflow page				0
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	4,556,956	0	4,556,956	528,265

LIABILITIES, CAPITAL AND SURPLUS

			Current Year		Prior Year
		1	2	3	4
		Covered	Uncovered	Total	Total
1.	Claims unpaid (less \$0 reinsurance ceded)				
2.	Accrued medical incentive pool and bonus amounts				
3.	Unpaid claims adjustment expenses				
4.	Aggregate health policy reserves, including the liability of		2,207,110	2,207,110	1,002,700
٦.	\$76,727 for medical loss ratio rebate per the Public				
	Health Service Act	28 933 017		28 933 017	59 292 828
5.	Aggregate life policy reserves				
6.	Property/casualty unearned premium reserves				
7.	Aggregate health claim reserves				
7. 8.	Premiums received in advance				
9.	General expenses due or accrued				
10.1				0,440,000	2, 100,509
10.1	(including \$ on realized capital gains (losses))	0		0	0
10.2	Net deferred tax liability				0
11.	Ceded reinsurance premiums payable.				
12.	Amounts withheld or retained for the account of others				
13.	Remittances and items not allocated				0,420,001
14.	Borrowed money (including \$ current) and				0
14.	interest thereon \$(including				
	\$ (including			0	0
15	Amounts due to parent, subsidiaries and affiliates.				
15.	Derivatives				
16.	Payable for securities.				0
17.	Payable for securities lending				
18.				0	0
19.	Funds held under reinsurance treaties (with \$				
	reinsurers and \$0 certified reinsurers)				0
00	,	-		0	
20.	Reinsurance in unauthorized and certified (\$			0	0
0.4	companies				
21.	Net adjustments in assets and liabilities due to foreign exchange rates Liability for amounts held under uninsured plans				0
22.				0	0
23.	Aggregate write-ins for other liabilities (including \$ current)		0	16 054 540	126 120
0.4	·		23.464.861	286.576.831	
	Total liabilities (Lines 1 to 23)	· · · · · · · · · · · · · · · · · · ·		, , ,	257,315,426
25.	Aggregate write-ins for special surplus funds Common capital stock				
26.					
27.	Preferred capital stock.				116 702 107
28.	Gross paid in and contributed surplus				
29.					
30.	Aggregate write-ins for other than special surplus funds				
31.	Unassigned funds (surplus)	XXX	XXX	177,042,743	180,244,731
32.	Less treasury stock, at cost:				
	32.1shares common (value included in Line 26	2007	2007		
	\$	xxx	XXX		
	32.2shares preferred (value included in Line 27	3007	2007		
	\$				000 704 000
33.	Total capital and surplus (Lines 25 to 31 minus Line 32)				
34.	Total liabilities, capital and surplus (Lines 24 and 33)	XXX	XXX	613,953,794	586,050,035
000	DETAILS OF WRITE-INS	10.051.510		40.054.540	
	Nursing Facility Pass Through Accrual				
	Fines and Penalties				436,430
2303.					
2398.	Summary of remaining write-ins for Line 23 from overflow page				
2399.	Totals (Lines 2301 thru 2303 plus 2398)(Line 23 above)		0	16,954,542	436,430
	Health Insurance Industry Fee				
2502.					
2503.					
2598.	Summary of remaining write-ins for Line 25 from overflow page				0
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	XXX	XXX	30,531,093	29,286,730
3001.					
3002.		XXX	XXX		
3003.		xxx	XXX		
3098.	Summary of remaining write-ins for Line 30 from overflow page	XXX	XXX	0	0
3099.	Totals (Lines 3001 thru 3003 plus 3098)(Line 30 above)	XXX	XXX	0	0

STATEMENT OF REVENUE AND EXPENSES

	STATEMENT OF REVENUE AN			5: 1/
		Curren 1	t Year 2	Prior Year 3
		Uncovered	Total	Total
1.	Member Months.	xxx	1,959,109	6,328,529
				, ,
2.	Net premium income (including \$ non-health premium income)	xxx	2 209 296 062	2 203 228 301
	,			
3.	Change in unearned premium reserves and reserve for rate credits			
4.	Fee-for-service (net of \$ medical expenses)	XXX	0	
5.	Risk revenue	XXX	0	
6.	Aggregate write-ins for other health care related revenues	XXX	4,203,769	2,193,390
7.	Aggregate write-ins for other non-health revenues			
	Total revenues (Lines 2 to 7)			
8.			2,213,499,031	2,200,421,091
•	Hospital and Medical:		1 040 400 440	004 450 055
9.	Hospital/medical benefits			
10.	Other professional services		31,542,747	28,270,158
11.	Outside referrals	229,297,140	229,297,140	293,500,109
12.	Emergency room and out-of-area	6,799,073	45,919,506	29,285,943
13.	Prescription drugs			
	•			
14.	Aggregate write-ins for other hospital and medical.			
15.	Incentive pool, withhold adjustments and bonus amounts			
16.	Subtotal (Lines 9 to 15)	236,096,213	1,815,181,348	1,823,249,406
	Less:			
17.	Net reinsurance recoveries		0	
18.	Total hospital and medical (Lines 16 minus 17)	236.096.213	1.815.181.348	1.823.249.406
19.	Non-health claims (net)			
	. ,			
20.	Claims adjustment expenses, including \$130,673,460 cost containment expenses	143,828,585	143,828,585	140,299,062
21.	General administrative expenses		223,274,842	192,290,949
22.	Increase in reserves for life and accident and health contracts (including \$			
	increase in reserves for life only)		(30,245,047)	36,019,852
23.	Total underwriting deductions (Lines 18 through 22)			
24.	Net underwriting gain or (loss) (Lines 8 minus 23)			
25.	Net investment income earned (Exhibit of Net Investment Income, Line 17)			
26.	Net realized capital gains (losses) less capital gains tax of \$		(48,018)	
27.	Net investment gains (losses) (Lines 25 plus 26)	0	8,451,012	10,043,997
28.	Net gain or (loss) from agents' or premium balances charged off [(amount recovered			
	\$) (amount charged off \$		(573 733)	(6 313 070)
29.	Aggregate write-ins for other income or expenses	0	(33,421)	(12,216)
30.	Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus	VVV	60 202 061	17,281,124
	27 plus 28 plus 29)			
31.	Federal and foreign income taxes incurred	XXX	23,249,251	23,867,183
32.	Net income (loss) (Lines 30 minus 31)	XXX	46,054,710	(6,586,059)
	DETAILS OF WRITE-INS			
0601.	Health Industry Fee Recoupment	XXX	4,203,769	2,193,390
0602.	,	XXX		
0603		XXX		
0698.		XXX	0	
0699.	Totals (Lines 0601 thru 0603 plus 0698)(Line 6 above)	XXX	4,203,769	2,193,390
0701.		XXX		
0702.		XXX		
0703		XXX		
0798.	Summary of remaining write-ins for Line 7 from overflow page	XXX	0	0
0799.	Totals (Lines 0701 thru 0703 plus 0798)(Line 7 above)	XXX	0	0
1401.	ì			
1402.				
-				
1403.		0		•
1498.		0	0	0
1499.	Totals (Lines 1401 thru 1403 plus 1498)(Line 14 above)	0	0	0
2901.	Penalties and Fines	0	(33,421)	(12,216)
2902.				
2903				
2998.	Summary of remaining write-ins for Line 29 from overflow page	0	0	0
2999.	Totals (Lines 2901 thru 2903 plus 2998)(Line 29 above)	0	(33,421)	(12,216)
		• 1	(00, 121)	(12,210)

STATEMENT OF REVENUE AND EXPENSES (Continued)

4,734,967 6,586,059
5,586,059
5,586,059
5,586,059
5,586,059
5,586,059
5,586,059
,934,918
7,304,310
(040 017
.(949,217
0
0
0
0
0
0
7,400,000
0
3,000,358
3,734,609
0
7

CASH FLOW

		1	2
	Ocal from Occuptions	Current Year	Prior Year
	Cash from Operations	0 104 040 100	0 100 707 000
	Premiums collected net of reinsurance		2,168,767,220
	Net investment income		15,692,058
	Miscellaneous income		0 101 150 070
	Total (Lines 1 through 3)		2,184,459,278
	Benefit and loss related payments		1,868,292,686
	Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts		
7. (Commissions, expenses paid and aggregate write-ins for deductions	349,541,307	451,539,024
8. [Dividends paid to policyholders		
9. F	Federal and foreign income taxes paid (recovered) net of \$ tax on capital gains (losses)	9,900,664	40,244,044
10.	Total (Lines 5 through 9)	2,106,271,373	2,360,075,754
11.	Net cash from operations (Line 4 minus Line 10)	103,716,862	(175,616,476)
	Cash from Investments		
12. F	Proceeds from investments sold, matured or repaid:		
	•	57,223,619	117 061 765
	12.1 Bonds		, ,
	12.2 Stocks		0
	12.3 Mortgage loans		0
	12.4 Real estate		0
	12.5 Other invested assets		0
	12.6 Net gains or (losses) on cash, cash equivalents and short-term investments		(1,498)
1	12.7 Miscellaneous proceeds		0
1	12.8 Total investment proceeds (Lines 12.1 to 12.7)	57,224,685	117,260,267
	Cost of investments acquired (long-term only):		
1	13.1 Bonds	92,169,111	65,856,051
1	13.2 Stocks	0	0
1	13.3 Mortgage loans	0	0
1	13.4 Real estate	0	0
1	13.5 Other invested assets	0	0
1	13.6 Miscellaneous applications	0	0
1	13.7 Total investments acquired (Lines 13.1 to 13.6)	92,169,111	65,856,051
14. N	Net increase (decrease) in contract loans and premium notes	0	0
15. N	Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14)	(34,944,426)	51,404,216
16. (Cash from Financing and Miscellaneous Sources Cash provided (applied):		
	16.1 Surplus notes, capital notes	0	0
	16.2 Capital and paid in surplus, less treasury stock		0
	16.3 Borrowed funds		
	16.4 Net deposits on deposit-type contracts and other insurance liabilities		
			0
	16.5 Dividends to stockholders		57,400,000
	16.6 Other cash provided (applied)		10,239,580
17. ľ	Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)	(4,034,337)	(47, 160, 420)
	RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS		
18.	Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	64,738,098	(171,372,680)
	Cash, cash equivalents and short-term investments:		
	19.1 Beginning of year	15,296,468	186,669,148
	19.2 End of year (Line 18 plus Line 19.1)	80,034,566	15,296,468

Note: Supplemental disclosures of cash flow information for non-cash transactions:	

ANALYSIS OF OPERATIONS BY LINES OF BUSINESS

		<i>,</i> 11	IAL I OIO O		TITOITO D		OI DOOMINE				
		1	2	3	4	5	6 Federal Employees	7 Title	8 Title	9	10
		Total	Comprehensive (Hospital & Medical)	Medicare Supplement	Dental Only	Vision Only	Health Benefits Plan	XVIII Medicare	XIX Medicaid	Other Health	Other Non-Health
1	Net premium income	2,209,296,062	(Hoopital & Wooloal)	Сарріотіоті	Only	Only	Donomo i idii	1,381,577,147	825,835,340	1,883,575	Hom Hould
	Change in unearned premium reserves and reserve for rate credit	0							320,000,010	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
3.	Fee-for-service (net of \$										
	medical expenses)	0									XXX
4.	Risk revenue	0									XXX
	revenues	4,203,769	0	0	Ω	0	0	0	4,203,769	0	XXX
6.	Aggregate write-ins for other non-health care related revenues	0	xxx	xxx	xxx	xxx	xxx	xxx	xxx	xxx	0
7.	Total revenues (Lines 1 to 6)	2,213,499,831	0	0	0	0	0	1,381,577,147		1,883,575	0
8.	Hospital/medical benefits	1,318,109,140						818,039,710	500,069,430		XXX
9.	Other professional services	31,542,747						26,855,649	4,687,098		XXX
10.	Outside referrals	229,297,140						154,990,912	74,306,228		XXX
11.	Emergency room and out-of-area	45,919,506						31, 185, 779	14,733,727		XXX
12.	Prescription drugs	193,890,108						98,837,191	104,928,877	(9,875,961)	XXX
13.	Aggregate write-ins for other hospital and medical	0	0	0	0	0	0	0 L	0	0	XXX
14.	Incentive pool, withhold adjustments and bonus amounts	(3,577,293)						(4,768,722)	1, 191, 429		XXX
15.	Subtotal (Lines 8 to 14)	1,815,181,348	0	0	0	0	0	1, 125, 140, 520	699,916,789	(9,875,961)	XXX
16.	Net reinsurance recoveries	0									XXX
17.	Total medical and hospital (Lines 15 minus 16)	1,815,181,348	0	0	0	0	0	1, 125, 140, 520	699,916,789	(9,875,961)	XXX
18.	Non-health claims (net)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
19.	Claims adjustment expenses including \$130,673,460 cost containment expenses	143,828,585						86,983,297	56,826,301	18,986	
20.	General administrative expenses	223,274,842						119,527,844	103,244,902	502,097	
21.	Increase in reserves for accident and health contracts	(30,245,047)							(30,245,047)		XXX
22.	Increase in reserves for life contracts	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
23.	Total underwriting deductions (Lines 17 to 22)	2, 152, 039, 729	0	0	0	0	0	1,331,651,662	829,742,945	(9,354,878)	0
24.	Total underwriting gain or (loss) (Line 7 minus Line 23)	61,460,103	0	0	0	0	0	49,925,485	296, 164	11,238,453	0
0501.	DETAILS OF WRITE-INS Health Industry Fee Recoupment	4,203,769							4,203,769		XXX
0501.											XXX
0502.						†	<u> </u>				XXX
0598.	Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	0	XXX
0599.	Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	4,203,769	ر ا م	 Ω	n	0	ا ۸	0	4,203,769	0	XXX
0601.	istato (Enico coo i tina coco pias coso) (Enico above)	4,200,709	XXX	XXX	XXX	XXX	XXX	XXX	XXX XXX	XXX	////
0601.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0602.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
	Summary of remaining write-ins for Line 6 from overflow										
0000.	page	0	XXX	XXX	xxx	xxx	XXX	XXX	XXX	xxx	0
0699.	Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
1301.											XXX
1302.											XXX
1303.											XXX
1398.	Summary of remaining write-ins for Line 13 from overflow page	0	0	0	0	0	0	0	0	0	XXX
1399	Totals (Lines 1301 thru 1303 plus 1398) (Line 13 above)	n l	n	 0	n	0	n	0	n	0	XXX
1000.	Totalo (Ellios 1001 tilla 1000 pius 1000) (Ellie 10 above)	U	v I	U			, ,,	٥	٥١	٠	/V//\

UNDERWRITING AND INVESTMENT EXHIBIT

PART 1 - PREMIUMS

	1	2	3	4
Line of Business	Direct Business	Reinsurance Assumed	Reinsurance Ceded	Net Premium Income (Cols. 1 + 2 - 3)
Comprehensive (hospital and medical)				0
2. Medicare Supplement				0
3. Dental only				0
4. Vision only				0
5. Federal Employees Health Benefits Plan	0			0
6. Title XVIII - Medicare	1,381,577,147			1,381,577,147
7. Title XIX - Medicaid	825,835,340			825,835,340
8. Other health	1,883,575			1,883,575
9. Health subtotal (Lines 1 through 8)	2,209,296,062	0	0	2,209,296,062
10. Life	0			0
11. Property/casualty	0			0
12. Totals (Lines 9 to 11)	2,209,296,062	0	0	2,209,296,062

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2 - CLAIMS INCURRED DURING THE YEAR

					IMS INCURRED DO	NING THE TEAN					
		1	2	3	4	5	6 Federal	7	8	9	10
		Total	Comprehensive (Hospital & Medical)	Medicare Supplement	Dental Only	Vision Only	Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Other Health	Other Non-Health
1.	Payments during the year:										
	1.1 Direct	1,749,935,179						1, 126, 594, 168	688,272,236	(64,931,225)	
	1.2 Reinsurance assumed	0									
	1.3 Reinsurance ceded	0									
	1.4 Net	1,749,935,179	0	0	0	0	0	1, 126, 594, 168	688,272,236	(64,931,225)	
2.	Paid medical incentive pools and bonuses	(3, 105, 776)						(4, 105, 533)	999,757		
3.	·										
	3.1 Direct	143,364,561	0	0	0	0	0	81,712,296	57,066,338	4,585,927	
	3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	(
	3.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	(
	3.4 Net	143,364,561	0	0	0	0	0	81,712,296	57,066,338	4,585,927	(
4.		0									
	4.2 Reinsurance assumed	۰									
	4.3 Reinsurance ceded										
		0			Δ	Λ					
_	4.4 Net	0			0	0		U			
5.	year	9,230,620						9,038,948	191,672		
6.		(60, 168, 769)						508,438	1,940,151	(62,617,358)	
	Amounts recoverable from reinsurers December 31, current year	0									
8.	Claim liability December 31, prior year from Part 2A:										
	8.1 Direct	134,709,867	0	0	0	0	0	77,888,784	44,673,063	12,148,021	
	8.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	
	8.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	(
	8.4 Net	134,709,867	0	0	0	0	0	77,888,784	44,673,063	12,148,021	
9.	Claim reserve December 31, prior year from Part 2D:	0									
	9.2 Reinsurance assumed	n									
	9.3 Reinsurance ceded	n									
	9.4 Net	n l	n	0	Λ	n .	n	n -	n	n	(
10	Accrued medical incentive pools and bonuses, prior year	9.702.137						9,702,137			
11.	Amounts recoverable from reinsurers December 31, prior year	0,702,107						0,762,107			
10	Incurred Benefits:	0									
12.	12.1 Direct	1,818,758,641	0	0	n	n	0	1,129,909,242	698,725,360	(9,875,961)	(
	12.2 Reinsurance assumed	1,010,730,041 0			 n			1, 123,303,242		(8,010,901)	
		0 N			ا ۱	0 N		۲		٠٠٠٠	ا
	12.3 Reinsurance ceded	1,818,758,641	0	0	0	0	0	1,129,909,242	698,725,360	(9,875,961)	
4.0	12.4 Net		0		ŭ	ū	-				
13.	Incurred medical incentive pools and bonuses	(3,577,293)	0	0	0	0	0	(4,768,722)	1,191,429	0	(

(a) Excludes \$ loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

				IS LIABILITY LIND			,			
	1	2	3	4	5	6 Federal Employees	7 Title	8 Title	9	10
	Total	Comprehensive (Hospital & Medical)	Medicare Supplement	Dental Only	Vision Only	Health Benefits Plan	XVIII Medicare	XIX Medicaid	Other Health	Other Non-Health
Reported in Process of Adjustment:										
1.1 Direct	17,580,938						12,917,993	77,018	4,585,927	
1.2 Reinsurance assumed	0									
1.3 Reinsurance ceded	0									
1.4 Net	17,580,938	0	0	0	0	0	12,917,993	77,018	4,585,927	0
Incurred but Unreported:										
2.1 Direct	125,783,623						68,794,303	56,989,320		
2.2 Reinsurance assumed	0									
2.3 Reinsurance ceded	0									
2.4 Net	125,783,623	0	0	0	0	0	68,794,303	56,989,320	0	0
3. Amounts Withheld from Paid Claims and Capitations:										
3.1 Direct	0									
3.2 Reinsurance assumed	0									
3.3 Reinsurance ceded	0									
3.4 Net	0	0	0	0	0	0	0	0	0	0
4. TOTALS:										
4.1 Direct	143,364,561	0	0	0	0	0	81,712,296	57,066,338	4,585,927	0
4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
4.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
4.4 Net	143,364,561	0	0	0	0	0	81,712,296	57,066,338	4,585,927	0

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2B - ANALYSIS OF CLAIMS LINPAID - PRIOR YEAR - NET OF REINSURANCE

	Claims Paid D	Claims Paid During the Year			5	6
	1	2	3	4		Estimated Claim Reserve and Claim
Line of Business	On Claims Incurred Prior to January 1 of Current Year	On Claims Incurred During the Year	On Claims Unpaid December 31 of Prior Year	On Claims Incurred During the Year	Claims Incurred In Prior Years (Columns 1 + 3)	Liability December 31 of Prior Year
Comprehensive (hospital and medical)	0. 04.10.1.	Daning are real		During and You.	0	0
2. Medicare Supplement					0	0
Dental Only					0	0
4. Vision Only					0	0
5. Federal Employees Health Benefits Plan					0	0
6. Title XVIII - Medicare	34,815,371	1,091,778,797	1,267,871	80,444,425	36,083,242	77,888,784
7 Title XIX - Medicaid	31,787,641	656,484,594	55,203	57,011,135	31,842,844	44,673,063
8. Other health	(65,098,671)	167,446	4,585,512	415	(60,513,159)	12,148,021
9. Health subtotal (Lines 1 to 8)	1,504,341	1,748,430,838	5,908,587	137,455,974	7,412,928	134,709,867
10. Healthcare receivables (a)			5,339,962	27,802,787	5,339,962	93,311,519
11. Other non-health					0	0
12. Medical incentive pools and bonus amounts	3,485,625	(6,591,401)	2,140,345	7,090,275	5,625,970	9,702,137
13. Totals (Lines 9 - 10 + 11 + 12)	4,989,966	1,741,839,437	2,708,970	116,743,462	7,698,936	51,100,486

⁽a) Excludes \$ loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (000 Omitted)

Section A - Paid Health Claims - Title XVIII

		Cumulative Net Amounts Paid							
		1	2	3	4	5			
	Year in Which Losses Were Incurred	2011	2012	2013	2014	2015			
1.	Prior	47,055	47,331	47,211	47,212	47,212			
2.	2011	781,486	845,545	845,709	845,638	845,638			
3.	2012	XXX	900,535	963,970	965,280	965,322			
4.	2013	XXX	XXX	1,008,100	1,082,842	1,083,037			
5.	2014	XXX	XXX	XXX	1,055,722	1,093,785			
6.	2015	XXX	XXX	XXX	XXX	1,083,679			

Section B - Incurred Health Claims - Title XVIII

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year						
	1 2 3 4 5						
Year in Which Losses Were Incurred	2011	2012	2013	2014	2015		
1. Prior	200,467	47,331	47,211	47,212	47,212		
2. 2011	860,109	847,455	845,709	845,638	845,638		
3. 2012	XXX	993,636	966,554	965,280	965,322		
4. 2013	XXX	XXX	1, 118, 117	1,086,378	1,083,037		
5. 2014	XXX	XXX	XXX	1, 139,777	1,097,193		
6. 2015	XXX	XXX	XXX	XXX	1,171,022		

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XVIII

	1	2	3	4	5	6	7	8	9	10
					Claim and Claim				Total Claims and	
Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1. 2011	1,104,518	845,638	49,137	5.8	894,775	81.0			894,775	81.0
2. 2012	1,239,906	965,322	67,270	7.0	1,032,592	83.3			1,032,592	83.3
3. 2013	1,310,114	1,083,037	60,497	5.6	1, 143, 534	87.3			1,143,534	87.3
4. 2014	1,363,018	1,093,785	83,542	7.6	1, 177, 327	86.4	3,408	48	1,180,784	86.6
5. 2015	1,388,482	1,083,679	76,277	7.0	1,159,956	83.5	87,343	1,243	1,248,542	89.9

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (000 Omitted)

Section A - Paid Health Claims - Title XIX

		Cumulative Net Amounts Paid							
		1	2	3	4	5			
	Year in Which Losses Were Incurred	2011	2012	2013	2014	2015			
1.	Prior	0	0	0	0	0			
2.	2011	2,899	4,622	4,601	4,601	4,601			
3.	2012	XXX	170,142	184 , 132	183,924	183,829			
4.	2013	XXX	XXX	248,602	265,800	265,837			
5.	2014	XXX	XXX	XXX	314,211	346,056			
6.	2015	XXX	XXX	XXX	XXX	655,544			

Section B - Incurred Health Claims - Title XIX

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year							
	1 2 3 4 5							
Year in Which Losses Were Incurred	2011	2012	2013	2014	2015			
1. Prior	0	0	0	0	0			
2. 2011	4,932	4,635	4,601	4,601	4,601			
3. 2012	XXX	194,730	184,408	183,924	183,829			
4. 2013	XXX	XXX	265,307	265,850	265,837			
5. 2014	XXX	XXX	XXX	358,835	346,111			
6. 2015	XXX	XXX	XXX	XXX	712,747			

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XIX

	1	2	3	4	5	6	7	8	9	10
					Claim and Claim				Total Claims and	
Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1. 2011	6,812	4,601	0	0.0	4,601	67.5			4,601	67.5
2. 2012	208,756	183,829	(9)	0.0	183,819	88.1			183,819	88.1
3. 2013	316,539	265,837	3,089	1.2	268,926	85.0			268,926	85.0
4. 2014	408,639	346,056	29,280	8.5	375,336	91.9	55	1	375,392	91.9
5. 2015	830,045	655,544	49,937	7.6	705,481	85.0	57,203	995	763,678	92.0

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (000 Omitted)

Section A - Paid Health Claims - Other

		Cumulative Net Amounts Paid							
		1	2	3	4	5			
	Year in Which Losses Were Incurred	2011	2012	2013	2014	2015			
1.	Prior	(31,995)	(31,995)	(31,995)	(31,995)	(31,995)			
2.	2011	837,213	799,307	799,307	799,307	799,307			
3.	2012	XXX	559,119	553, 148	553,148	553,148			
4.	2013	XXX	XXX	409,630	392,307	392,307			
5.	2014	XXX	XXX	XXX	409,957	344,858			
6.	2015	XXX	XXX	XXX	XXX	62,785			

Section B - Incurred Health Claims - Other

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonus Outstanding at End of Year						
	1 2 3 4						
Year in Which Losses Were Incurred	2011	2012	2013	2014	2015		
1. Prior	9,582	(31,995)	(31,995)	(31,995)	(31,995)		
2. 2011	905,505	799,561	799,307	799,307	799,307		
3. 2012	XXX	616,672	555,636	553,148	553,148		
4. 2013	XXX	XXX	454,260	395,654	392,307		
5. 2014	XXX	XXX	XXX	418,758	349,443		
6. 2015	XXX	XXX	XXX	XXX	62,785		

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Other

	1	2	3	4	5	6	7	8	9	10
					Claim and Claim				Total Claims and	
Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1. 2011	961,049	799,307	32,493	4.1	831,800	86.6			831,800	86.6
2. 2012	719,125	553,148	14,800	2.7	567,948	79.0			567,948	79.0
3. 2013	499,921	392,307	12,737	3.2	405,044	81.0			405,044	81.0
4. 2014	431,570	344,858	27,716	8.0	372,574	86.3	4,586	0	377,160	87.4
5. 2015	(9,346)	62,785	539	0.9	63,324	(677.6)	0	0	63,325	(677.6)

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (000 Omitted)

Section A - Paid Health Claims - Grand Total

		Cumulative Net Amounts Paid						
		1	2	3	4	5		
	Year in Which Losses Were Incurred	2011	2012	2013	2014	2015		
1.	Prior	15,060	15,336	15,216	15,217	15,217		
2.	2011	1,621,597	1,649,475	1,649,618	1,649,547	1,649,547		
3.	2012	XXX	1,629,795	1,701,250	1,702,351	1,702,299		
4.	2013	XXX	XXX	1,666,332	1,740,949	1,741,181		
5.	2014	XXX	XXX	XXX	1,779,889	1,784,699		
6.	2015	XXX	XXX	XXX	XXX	1,802,008		

Section B - Incurred Health Claims - Grand Total

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuse Outstanding at End of Year						
	1 2 3 4 5						
Year in Which Losses Were Incurred	2011	2012	2013	2014	2015		
1. Prior	210,049	15,336	15,216	15,217	15,217		
2. 2011	1,770,547	1,651,651	1,649,617	1,649,547	1,649,547		
3. 2012	XXX	1,805,038	1,706,598	1,702,351	1,702,299		
4. 2013	XXX	XXX	1,837,684	1,747,881	1,741,181		
5. 2014	XXX	XXX	XXX	1,917,369	1,792,748		
6. 2015	XXX	XXX	XXX	XXX	1,946,554		

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Grand Total

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2011	2,072,379	1,649,547	81,630	4.9	1,731,177	83.5	0	0	1,731,177	83.5
2.	2012	2,167,787	1,702,299	82,061	4.8	1,784,359	82.3	0	0	1,784,359	82.3
3.	2013	2,126,574	1,741,181	76,323	4.4	1,817,505	85.5	0	0	1,817,505	85.5
4.	2014	2,203,228	1,784,699	140,538	7.9	1,925,237	87.4	8,049	49	1,933,335	87.8
5.	2015	2,209,181	1,802,008	126,753	7.0	1,928,761	87.3	144,546	2,238	2,075,545	94.0

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY

	PART 2D - AC	GGREGATE RESER		T AND HEALTH CO	NTRACTS ONLY				
	1	2 Comprehensive	3 Medicare	4	5	6 Federal Employees Health	7 Title XVIII	8 Title XIX	9
	Total	(Hospital & Medical)	Supplement	Dental Only	Vision Only	Benefits Plan	Medicare	Medicaid	Other
Unearned premium reserves	0								
Additional policy reserves (a)	14,982,414							14,982,414	
Reserve for future contingent benefits	0								
Reserve for rate credits or experience rating refunds (including									
\$) for investment income	6,003,551						776,727	5,226,824	
Aggregate write-ins for other policy reserves	7,947,052	0	0	0	0	0	6,573,771	408, 100	965 , 182
6. Totals (gross)	28,933,017	0	0	0	0	0	7,350,498	20,617,338	965 , 182
7. Reinsurance ceded	0								
8. Totals (Net)(Page 3, Line 4)	28,933,017	0	0	0	0	0	7,350,498	20,617,338	965 , 182
9. Present value of amounts not yet due on claims	0								
10. Reserve for future contingent benefits	0								
11. Aggregate write-ins for other claim reserves	0	0	0	0	0	0	0	0	0
12. Totals (gross)	0	0	0	0	0	0	0	0	0
13. Reinsurance ceded	0								
14. Totals (Net)(Page 3, Line 7)	0	0	0	0	0	0	0	0	(
DETAILS OF WRITE-INS									
0501. CMS Risk Corridor	7,947,052						6,573,771	408,100	965 , 182
0502.									
0503.									
0598. Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	0
0599. Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	7,947,052	0	0	0	0	0	6,573,771	408,100	965, 182
1101.									
1102.									
1103.									
1198. Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0	0	0	0	0	
1199. Totals (Lines 1101 thru 1103 plus 1198) (Line 11 above)	0	0	0	0	0	0	0	0	(

(a) Includes \$ _____14,982,414 premium deficiency reserve.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 3 - ANALYSIS OF EXPENSES

			YSIS OF EXPENSE			_
	<u> </u>	Claim Adjustme 1	2	3	4	5
		Cost Containment Expenses	Other Claim Adjustment Expenses	General Administrative Expenses	Investment Expenses	Total
1.	Rent (\$0 for occupancy of					
	own building)	3,027,250	249,534	5,940,681		9,217,465
2.	Salary, wages and other benefits	54,372,993	7,122,488	94,005,541		155,501,023
3.	Commissions (less \$0					
	ceded plus \$0 assumed)	13,117,499	1,075,277	25,954,850		40 , 147 , 625
4.	Legal fees and expenses	1,500	10	11,536		13,046
5.	Certifications and accreditation fees					0
6.	Auditing, actuarial and other consulting services	8,143,983	2,552,842	15,821,137		26,517,963
7.	Traveling expenses	1,813,339	170,783	3,339,873		5,323,995
8.	Marketing and advertising	2,710,119	219,851	5,466,464		8,396,434
9.	Postage, express and telephone	2,345,812	226,417	4,413,765		6,985,994
10.	Printing and office supplies	2,271,755	191,554	4,200,049		6,663,358
11.	Occupancy, depreciation and amortization					0
12.	Equipment	450,853	46,613	873,023		1,370,489
13.	Cost or depreciation of EDP equipment and software	(1,875)	(188)	(1,985)		(4,049
14.	Outsourced services including EDP, claims, and other services					
15.	Boards, bureaus and association fees			215,313		
16.	Insurance, except on real estate					
17.	Collection and bank service charges					
18.	Group service and administration fees					
19.	Reimbursements by uninsured plans					
20.	Reimbursements from fiscal intermediaries					
21.	Real estate expenses					
22.	·		(1,033).	(30,400)		_
23.	Taxes, licenses and fees:					
20.	23.1 State and local insurance taxes			92,335		92,335
	23.2 State premium taxes			ŕ		,
	23.3 Regulatory authority licenses and fees		11			189,528
	23.4 Payroll taxes		427,827	5,482,730		
	23.5 Other (excluding federal income and real estate taxes)					31,287,189
24.	Investment expenses not included elsewhere		0	0		328.933
24. 25.	Aggregate write-ins for expenses		653,407	7,283,505		11,580,091
			13, 155, 124	223,274,842		
26.	Total expenses incurred (Lines 1 to 25)					1 ,
27.	Less expenses unpaid December 31, current year			8,446,856		10,733,965
28. 29.	Add expenses unpaid December 31, prior year Amounts receivable relating to uninsured plans,			2,100,569		4,033,298
30.	Amounts receivable relating to uninsured plans,			140,570,807		140,570,807 144,178,200
31.	Total expenses paid (Lines 26 minus 27 plus 28	100 075 100	12 000 017		220 022	
	minus 29 plus 30) DETAILS OF WRITE-INS	130,375,188	13,099,017	220,535,948	328,933	364,339,086
2501.	Other General Expenses	3,099,283	254,062	6,148,526		9,501,871
2502.	Part D Admin Fees		34,344	860,793		1,306,017
2503.	Stipends - Medical Director		10,620	269,686		
	Summary of remaining write-ins for Line 25 from overflow page		354,380	4,500	0	358,880
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25					
	above) des management fees of \$	3,643,180	653,407	7,283,505 n-affiliates.	0	11,580,091

(a) Includes management fees of \$283,417,838 to affiliates and \$ to non-affiliates

EXHIBIT OF NET INVESTMENT INCOME

		1	2
		Collected During Year	Earned During Year
1.	U.S. government bonds	(a)122,048	113,350
1.1	Bonds exempt from U.S. tax	(a)	
1.2	Other bonds (unaffiliated)	(a)8,497,191	8,691,315
1.3	Bonds of affiliates	(a)	
2.1	Preferred stocks (unaffiliated)	(b)	
2.11	Preferred stocks of affiliates	(b)	
2.2	Common stocks (unaffiliated)		
2.21	Common stocks of affiliates		
3.	Mortgage loans	(c)	
4.	Real estate	(d)	
5	Contract Loans		
6	Cash, cash equivalents and short-term investments	(e)19,322	26,111
7	Derivative instruments	(f)	
8.	Other invested assets		
9.	Aggregate write-ins for investment income	(492)	(492)
10.	Total gross investment income	8,638,069	8,830,284
11.	Investment expenses		(g)328,933
12.	Investment taxes, licenses and fees, excluding federal income taxes		(g)0
13.	Interest expense		(h)2,322
14.	Depreciation on real estate and other invested assets		(i)
15.	Aggregate write-ins for deductions from investment income		0
16.	Total deductions (Lines 11 through 15)		331,255
17.	Net investment income (Line 10 minus Line 16)		8,499,029
	DETAILS OF WRITE-INS		
0901.	Commitment Fee Income	(1,407)	(1,407)
0902.	Misc Inv Income	915	915
0903.			
0998.	Summary of remaining write-ins for Line 9 from overflow page	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)	(492)	(492)
1501.		` '	Ì
1502.			
1503.			
1598.	Summary of remaining write-ins for Line 15 from overflow page		
1599.	Totals (Lines 1501 thru 1503 plus 1598) (Line 15, above)		0
	, /		

(a) Includes \$	140,638	accrual of discount less \$4,647,425	amortization of premium and less \$304,981	paid for accrued interest on purchases.
(b) Includes \$		accrual of discount less \$	amortization of premium and less \$	paid for accrued dividends on purchases
(c) Includes \$		accrual of discount less \$	amortization of premium and less \$	paid for accrued interest on purchases.
(d) Includes \$		for company's occupancy of its own building	gs; and excludes \$ interest on encu	imbrances.
(e) Includes \$	26,702	accrual of discount less \$378	amortization of premium and less \$6,142	paid for accrued interest on purchases.
(f) Includes \$		accrual of discount less \$	amortization of premium.	
	and Separate Acco		investment taxes, licenses and fees, excluding fed	eral income taxes, attributable to
(h) Includes \$		interest on surplus notes and \$	interest on capital notes.	
(i) Includes \$		depreciation on real estate and \$	depreciation on other invested assets.	

EXHIBIT OF CAPITAL GAINS (LOSSES)

	LAIIDII	· · · · · ·	AL GAIII	- (/	_
		1	2	3	4	5
				Total Realized Capital	Change in	Change in Unrealized
		Realized Gain (Loss)	Other Realized	Gain (Loss)	Unrealized Capital	Foreign Exchange
		On Sales or Maturity	Adjustments	(Columns 1 + 2)	Gain (Loss)	Capital Gain (Loss)
1.	U.S. Government bonds	1,411	0	1,411	0	0
1.1	Bonds exempt from U.S. tax			0		
1.2	Other bonds (unaffiliated)	(3,468)	0	(3,468)	(466,119)	0
1.3	Bonds of affiliates	0	0	0	0	0
2.1	Preferred stocks (unaffiliated)	0	0	0	0	0
2.11	Preferred stocks of affiliates	0	0	0	0	0
2.2	Common stocks (unaffiliated)	0	0	0	0	0
2.21	Common stocks of affiliates	0	0	0	0	0
3.	Mortgage loans		0	0	0	0
4.	Real estate			0		0
5.	Contract loans			0		
6.	Cash, cash equivalents and short-term investments	1,066	0	1,066	0	0
7.	Derivative instruments			0		
8.	Other invested assets			0	0	0
9.	Aggregate write-ins for capital gains (losses)	0	0	0	0	0
10.	Total capital gains (losses)	(991)	0	(991)	(466,119)	0
	DETAILS OF WRITE-INS					
0901.						
0902.						
0903.						
0998.	Summary of remaining write-ins for Line 9 from overflow page	0	0	0	0	0
0000			U		U	
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)	0	0	0	0	0

EXHIBIT OF NON-ADMITTED ASSETS

		1 2				
		Current Year Total Nonadmitted Assets	Prior Year Total Nonadmitted Assets	Change in Total Nonadmitted Assets (Col. 2 - Col. 1)		
1.	Bonds (Schedule D)	. vonadmitod / toodio		0		
2.	Stocks (Schedule D):					
	2.1 Preferred stocks			0		
	2.2 Common stocks			0		
3.	Mortgage loans on real estate (Schedule B):					
	3.1 First liens			0		
	3.2 Other than first liens.			0		
4.	Real estate (Schedule A):					
	4.1 Properties occupied by the company			0		
	4.2 Properties held for the production of income.			_		
	4.3 Properties held for sale					
5.	Cash (Schedule E - Part 1), cash equivalents (Schedule E - Part 2) and short-term investments (Schedule DA)					
6.	Contract loans			0		
7.	Derivatives (Schedule DB)	_		0		
8.	Other invested assets (Schedule BA)	_		0		
9.	Receivables for securities			0		
10.	Securities lending reinvested collateral assets (Schedule DL)			0		
11.	Aggregate write-ins for invested assets	0	0	0		
12.	Subtotals, cash and invested assets (Lines 1 to 11)					
13.	Title plants (for Title insurers only)					
14.	Investment income due and accrued					
15.	Premiums and considerations:					
	15.1 Uncollected premiums and agents' balances in the course of collection		10,793	10,793		
	15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due			_		
	15.3 Accrued retrospective premiums and contracts subject to redetermination			_		
16.	Reinsurance:					
	16.1 Amounts recoverable from reinsurers			0		
	16.2 Funds held by or deposited with reinsured companies			_		
	16.3 Other amounts receivable under reinsurance contracts					
17.	Amounts receivable relating to uninsured plans			0		
18.1	Current federal and foreign income tax recoverable and interest thereon			0		
	Net deferred tax asset		642,595	42,777		
19.	Guaranty funds receivable or on deposit	,		0		
20.	Electronic data processing equipment and software			0		
21.	Furniture and equipment, including health care delivery assets			_		
22.	Net adjustment in assets and liabilities due to foreign exchange rates			0		
23.	Receivable from parent, subsidiaries and affiliates			0		
24.	Health care and other amounts receivable					
25.	Aggregate write-ins for other than invested assets					
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)					
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts			0		
28.	Total (Lines 26 and 27)	8,916,553	3,577,006	(5,339,547)		
	DETAILS OF WRITE-INS	2,010,000	3,011,000	(0,000,011)		
1101.	DETAILS OF WHITE-ING					
1102.						
1102.						
1198.	Summary of remaining write-ins for Line 11 from overflow page		0	0		
1198.		0	0	0		
	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)			0		
2501.						
2502.						
2503.	Commons of various units in fact line OF from quarters are		^	^		
2598.	Summary of remaining write-ins for Line 25 from overflow page		0	0		
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	0	0	0		

EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY

	EXTIBIT 1 ENTICEEMENT BY THOUSANT	Total Members at End of						
	Source of Enrollment	1 Prior Year	2 First Quarter	3 Second Quarter	4 Third Quarter	5 Current Year	Current Year Member Months	
1	Health Maintenance Organizations							
2	Provider Service Organizations							
3	Preferred Provider Organizations							
4	Point of Service							
5	Indemnity Only							
6	Aggregate write-ins for other lines of business.	511,731	163,060	163,790	164,402	166,636	1,959,109	
7	Total	511,731	163,060	163,790	164,402	166,636	1,959,109	
	DETAILS OF WRITE-INS							
0601	Medicare - Stand-alone Part D	354 , 153						
0602	Medicare Advantage	111, 153	110,719	110,621	111,262	113,514	1,334,940	
0603	Medicaid	46,425	52,341	53,169	53,140	53,122	624 , 169	
0698	Summary of remaining write-ins for Line 6 from overflow page	0	0	0	0	0	0	
0699	Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	511,731	163,060	163,790	164,402	166,636	1,959,109	

1. Summary of Significant Accounting Policies and Going Concern

On July 23, 2015, Cigna Corporation, Inc. (Cigna or Ultimate Parent) entered into a definitive agreement to merge with Anthem, Inc. (Anthem), subject to certain terms, conditions and customary operating covenants, with Anthem continuing as the surviving company. At special shareholders' meetings held in December 2015, Cigna shareholders approved the merger with Anthem and Anthem shareholders approved the issuance of shares of Anthem common stock according to the merger agreement. Consummation of the merger remains subject to certain customary conditions, including the receipt of certain necessary governmental and regulatory approvals and the absence of a legal restraint prohibiting the consummation of the merger. The merger is expected to close in the second half of 2016.

A. Accounting Practices

The financial statements of HealthSpring Life & Health Insurance Company, Inc. (the Company) are presented on the basis of accounting practices prescribed or permitted by the Texas Department of Insurance (the Department).

The Department recognizes only statutory accounting practices prescribed or permitted by the state of Texas for determining and reporting the financial condition and results of operations of a Health Maintenance Organization (HMO) for determining solvency under Texas Insurance Law. The National Association of Insurance Commissioners' (the NAIC) *Accounting Practices and Procedures Manual* (NAIC SAP) has been adopted as a component of prescribed or permitted practices by the state of Texas. While the Department has adopted certain prescribed accounting practices that differ from those found in NAIC SAP, the Company's financials were not affected by those differences in 2015 or 2014.

A reconciliation of the Company's net income and capital and surplus between NAIC SAP and practices prescribed and permitted by the Department is shown below:

State of Domicile		2015		2014
TX	\$	46,054,710	\$	(6,586,059)
TX		-		-
TX		-		
TX	\$	46,054,710	\$	(6,586,059)
TX	\$	327,376,963	\$	328,734,609
TX		-		-
TX		-		
TX	\$	327,376,963	\$	328,734,609
	Domicile TX TX TX TX TX TX	Domicile TX \$ TX TX TX TX TX TX TX TX	Domicile 2015 TX \$ 46,054,710 TX - TX \$ 46,054,710 TX \$ 327,376,963 TX - TX - TX - TX -	Domicile 2015 TX \$ 46,054,710 \$ TX - TX - TX \$ 46,054,710 \$ TX \$ 327,376,963 \$ TX - TX - TX -

B. Use of Estimates in the Preparation of the Financial Statements

The preparation of financial statements in conformity with NAIC SAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. It also requires disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. The most significant item subject to estimates and assumptions is the actuarially determined medical claims liabilities included in the financial statements. Other significant estimates are the

NOTES TO FINANCIAL STATEMENTS

estimated risk adjustment payments receivable from CMS, certain amounts recorded related the Medicare Part D program (Part D), and unpaid claims adjustment expenses.

Claims payable and liabilities for incurred but unreported claims are estimated by utilizing historical claims data and actuarial determined data, and adjusting the trend factors. Because actuarial information is utilized to project future liabilities, it is reasonably possible that the estimated liability may be adjusted in future periods upon receipt of more current information.

C. Accounting Policies

Net premium income on Medicare Advantage and Medicaid is due monthly from the Centers of Medicare and Medicaid Services (CMS) and the state of Texas and is recognized as revenue during the period in which the Company is obligated to provide services to members. Premiums collected in advance are deferred and recorded as advance payments.

Medicare Advantage premium revenue is subject to adjustment based on the health risk of its members. This process for adjusting premiums is referred to as the CMS risk adjustment payment methodology. Under the risk adjustment payment methodology, managed care plans must capture, collect, and report diagnosis code information to CMS. After reviewing the respective submissions, CMS establishes the payments to Medicare plans generally at the beginning of the calendar year, and then adjusts premium levels on two separate occasions on a retroactive basis. The first retroactive risk premium adjustment for a given fiscal year generally occurs during the third quarter of such fiscal year. This initial settlement (the Initial CMS Settlement) represents the updating of risk scores for the current year based on the prior year's dates of service. CMS then issues a final retroactive risk premium adjustment settlement for the fiscal year in the following year (the Final CMS Settlement). The Company estimates and records on a monthly basis both the Initial CMS Settlement and the Final CMS Settlement for the current CMS plan year. All such estimated amounts are periodically updated as necessary as additional diagnosis code information is reported to CMS and adjusted to actual amounts when the ultimate adjustment settlements are either received from CMS or the Company receives notification from CMS of such settlement amounts.

As a result of the variability of factors, including plan risk scores, that determine such estimations, the actual amount of CMS's retroactive risk premium settlement adjustments could be materially more or less than the Company's estimates. The Company's risk adjustment payments are subject to review and audit by CMS, which can potentially take several years to resolve completely. Any adjustment to net premium income and the related medical expense for risk-sharing arrangements with providers as a result of such review and audit would be recorded when estimable. There can be no assurance that any retroactive adjustment to previously recorded income or expenses will not have a material effect on future net income.

The Company provides prescription drug benefits pursuant to Part D. The Company refers to these plans collectively as Medicare Advantage plans and separately as Medicare Advantage (without Part D prescription drug benefits) and Medicare Advantage Part D (including Part D prescription drug benefits), or MA-PD plans.

Prescription drug benefits under Medicare Advantage plans vary in terms of coverage levels and out-of-pocket costs for premiums, deductibles, and coinsurance. All Part D plans are required by law to offer either standard coverage or its actuarial equivalent (with out-of-pocket threshold and deductible amounts that do not exceed those of standard coverage). In addition to standard coverage plans, the Company offers supplemental benefits in excess of the standard coverage.

To participate in Part D, the Company was required to provide written bids to CMS, which among other items, included the estimated costs of providing prescription drug benefits. Payments from CMS are based on these estimated costs. The monthly Part D payments the Company receives from CMS for Part D plans generally represent the Company's bid amount for providing insurance coverage, both standard and supplemental, and is recognized monthly as net premium income. The amount of CMS payments relating to the Part D standard coverage for MA-PD and PDP plans is subject to adjustment, positive or negative, based upon the application of risk corridors that compare the Company's prescription drug costs in its bids to CMS to the Company's actual prescription drug costs. Variances exceeding certain thresholds may result in CMS making additional payments to the Company or the Company's refunding to CMS a

portion of the premium payments it previously received. The Company estimates and recognizes an adjustment to net premium income related to estimated risk corridor payments based upon its actual prescription drug cost for each reporting period as if the annual contract were to end at the end of each reporting period, in accordance with NAIC Interpretation No. 05-05, *Accounting for Revenues under Medicare Part D Coverage*. Risk corridor adjustments do not take into account estimated future prescription drug costs

The Company recognizes net premium income for the Part D payments received from CMS for which it assumes risk. Certain Part D payments from CMS represent payments for claims the Company pays for which it assumes no risk. The Company accounts for these subsidies as amounts receivable relating to uninsured plans or liability for amounts held under uninsured plans on the balance sheet. The Company does not recognize premium income or hospital, medical, and pharmaceutical expenses for these subsidies as these amounts represent pass-through payments from CMS to fund deductibles, copayments, and other member benefits.

The Company recognizes prescription drug costs as incurred, net of rebates from drug companies. The Company has subcontracted the prescription drug claims administration to a third-party pharmacy benefit manager.

Medicaid experience rebate payable consists of estimates of amounts due under Medicaid contracts with the State of Texas. These amounts are computed based on a percentage of Medicaid profits as defined in the contract with the State. The profitability computation includes premium revenue earned from the state less actual medical and administrative costs incurred and paid and less estimated unpaid claims payable for applicable membership. The unpaid claims payable estimates are based on historical payment patterns using actuarial techniques. A final settlement is generally made 334 days after the contract period ends using paid claims data and is subject to audit by the State any time thereafter. Any adjustment made to the experience rebate payable as a result of final settlement is included in current operations.

Cost of care that is paid on a fee-for-service basis, a per diem basis, or other basis includes actual reported claims and an estimate of incurred but not reported (IBNR) claims. IBNR claims are estimated by using historical trends, current membership statistics, and other information. Cost of care paid on a capitation basis is recognized in the month of coverage. Cost of pharmaceuticals is recognized in the month incurred.

Acquisition costs are certain marketing costs that vary with, and are primarily related to, the acquisition of member contracts. These costs are expensed as incurred and are included in general and administrative expenses in the accompanying statement of revenue and expenses.

In the normal course of business, the Company enters into transactions involving various types of financial instruments. These financial instruments primarily include bonds on the balance sheet. These instruments may change in value due to interest rate and market fluctuations and most also have credit risk. The Company evaluates and monitors each financial instrument individually. The Company did not have any off-balance sheet financial instruments as of December 31, 2015 and 2014.

Fair values of financial instruments are based on quoted market prices when available. When market prices are not available, fair value is generally estimated using discounted cash flow analyses, incorporating current market inputs for similar financial instruments with comparable terms and credit quality. In instances where there is little or no activity for the same or similar instruments, the Company estimates fair value using methods, models, and assumptions that the Company believes a hypothetical market participant would use to determine a current transaction price.

Cash and cash equivalents consist of cash and short-term investments that will mature in three months or less from the time of purchase.

Health premiums due and uncollected are recorded during the period the Company is obligated to provide services to members and do not bear interest. The allowance for doubtful accounts is the Company's best estimate of the amount of probable losses in the Company's existing health premiums due and unpaid and is based on past-due balances greater than 90 days. Balances greater than 90 days past due which are not reserved are included as non-admitted assets. Account balances are charged off after all means of collection have been exhausted and the potential for recovery is considered remote.

NOTES TO FINANCIAL STATEMENTS

Health premiums under government insured plans, including amounts over 90 days due that qualify as accident and health contracts in accordance with SSAP No. 50, Classifications and Definitions of Insurance or Managed Care Contracts in Force, are included in admitted assets.

When interest and principal payments on bonds are current, the Company recognizes interest income when it is earned. The Company stops recognizing interest income when interest payments are 90 days past due or when certain terms (interest rate or maturity date) of the bond have been restructured. Investment income on these bonds is only recognized when interest payments are received.

Investments and investment income due and accrued are evaluated in accordance with SSAP No. 5R, *Liabilities, Contingencies, and Impairments of Assets – Revised* (SSAP 5R), to determine whether impairment exists. Any amounts determined to be uncollectible are written off through the statutory basis statements of income. No amounts were written off during 2015 or 2014.

Unrealized capital gains and losses on investments carried at fair value are reflected directly in unassigned surplus. Realized capital gains and losses resulting from sales and investment asset write-downs are based on specifically identified assets and are recognized in net income. The Company had no write-downs of investment assets in 2015 or 2014.

The Company is included in the consolidated United States federal income tax return filed by Cigna. Pursuant to the Tax Sharing Agreement with Cigna, federal income taxes are allocated to the Company as if it were filing on a separate return basis. The tax benefit of net operating losses, capital losses, and tax credits are funded to the extent they reduce the consolidated federal income tax liability. The Company generally recognizes deferred income taxes when assets and liabilities have different values for financial statement and tax reporting purposes (temporary differences). Limitations of the admitted amount of the deferred tax asset are calculated in accordance with SSAP No. 101, Income Taxes – A Replacement of SSAP No. 10R and SSAP No. 10 (SSAP 101). Additional detailed information about the Company's income taxes is disclosed in Note

In accordance with various SSAP's, certain assets or certain portions of assets are excluded from the Company's admitted assets on its balance sheet through a direct charge to unassigned surplus. These nonadmitted assets may include intangible assets, capitalized software, furniture and equipment, leasehold improvements, unsecured receivables, prepaid expenses, overdue insurance premiums and subsidiary investments. Certain assets are limited by factors, such as a percentage of surplus, as to the amounts that qualify as admitted assets. Such assets may include electronic data processing equipment and deferred taxes.

The Company elected to use rounding in reporting certain amounts within the statement. The amounts in this statement pertain to the entire Company's business.

In addition, the Company uses the following accounting policies:

- 1. Investments with a maturity greater than three months but less than one year at the time of purchase are included in short-term investments and are carried at amortized cost.
- 2. Investments in bonds and short-term investments designated highest quality (NAIC-1) and high quality (NAIC-2) are carried at amortized cost. All others are carried at the lesser of cost or fair value. Amortization of bond premium or discount is calculated using the scientific (constant yield) interest method. Bonds containing call provisions are amortized to call value/date which produces the lowest asset value (yield to worst). Investments with original maturities of less than one year from the time of purchase are classified as short-term. Bonds are considered impaired and their cost basis is written down to fair value through net income, when management expects a decline in value to persist (i.e., the decline is other-than-temporary).
- 3. Common stocks not applicable.
- 4. Preferred stocks not applicable.
- 5. Mortgage loans not applicable.

NOTES TO FINANCIAL STATEMENTS

- 6. Loan-backed bonds and structured securities are stated at amortized cost using the constant yield method. Significant changes in estimated cash flows from the original purchase assumptions are accounted for generally using the retrospective method. Significant changes in estimated cash flows from the original purchase assumptions for loan-backed and structured securities that have potential for loss of a significant portion of the original investment are accounted for using the prospective method. These securities are presented on the balance sheet as bonds.
- 7. Investments in subsidiaries, controlled, and affiliated (SCA) entities not applicable.
- 8. Investments in joint ventures, partnerships, and limited liabilities companies not applicable.
- 9. Derivatives not applicable.
- 10. Aggregate Policy Reserves: The Company includes an accrual for losses where it is probable that expected future health care costs and maintenance costs under a group of existing contracts will exceed anticipated future premiums and insurance recoveries on those contracts, known as Premium Deficiency Reserve (PDR). The Company does not utilize anticipated investment income as a factor in the premium deficiency calculation.
- 11. Unpaid claims and claims adjustment expenses represent the Company's liability for services that have been performed by providers for members that have not been settled. These liabilities include medical claims reported to the Company, as well as an actuarially determined estimate of claims that have been incurred but not yet reported to the Company. The IBNR component is based upon the Company's historical claims data, current enrollment, health services utilization statistics and other related information. Estimating IBNR is complex and involves a significant amount of judgment. Changes in this estimate can materially affect, either favorably or unfavorably, the Company's statement of revenues and expenses or overall financial position.

The Company develops its estimate of IBNR using standard actuarial development methodologies, including the completion factor method. This method estimates liabilities for claims based upon the historical lag between the month when services are rendered and the month claims are paid and takes into consideration factors such as expected medical cost inflation, seasonality patterns, product mix, and membership changes. The completion factor is a measure of how complete the claims paid to data are relative to the estimate of the total claims for services rendered for a given reporting period. Although the completion factors are generally reliable for older service periods, they are more volatile, and hence less reliable, for more recent periods, given that the typical billing lag for services can range from a week to as much as 90 days from the date of service. As a result, for the most recent two to four months, the estimate for incurred claims is developed from a trend factor analysis based upon per member per month claims trends experienced in the preceding months.

Each period, the Company reexamines the previously established estimates of claims payable and liabilities for incurred but unreported claims based on actual claim submissions and other relevant changes in facts and circumstances. As the estimated liabilities recorded in prior periods become more exact, the Company increases or decreases the amount of the estimates and includes the changes in hospital and medical expenses in the period in which the change is identified. In every annual reporting period, the Company's operating results include the effects of more completely developed estimates associated with prior years.

The Company contracts with physicians or provider groups to provide medical services to their members. The Company pays capitation or negotiated fees for defined services provided by the physicians. The Company and some of the physicians have entered into incentive sharing agreements. Under the terms of these agreements, certain providers are eligible to receive a provider bonus based on qualitative and quantitative factors. Incentive sharing balances are estimated using current experience to calculate the current receivable or payable for each contract. These estimates may be adjusted based on actual experience and contract terms. The incentive sharing receivables and payables are reported gross on the balance sheet. Incentive sharing receivables are admitted in accordance with SSAP No. 84, *Certain Health Care Receivables and Receivables Under Government Insured Plans*.

NOTES TO FINANCIAL STATEMENTS

Included in hospital, medical, and pharmaceutical expenses are claim payments, capitation payments, risk-sharing payments, and pharmacy costs, net of rebates, as well as estimates of future payments of claims provided for services rendered prior to year-end. Capitation payments represent monthly contractual fees disbursed to physicians and other providers who are responsible for providing medical care to members. Risk sharing payments represent amounts paid under risk sharing arrangements with providers including independent physician associations. Pharmacy costs represent payments for members' prescription drug benefits, net of rebates from drug manufacturers. Rebates are recognized when the rebates are earned according to the contractual arrangements with the respective vendors.

- 12. The Company has not modified its capitalization policy from the prior period.
- 13. Pharmacy rebate receivables consist of reasonably estimable amounts, based upon utilization data and past history, and billed amounts to pharmaceutical companies. The income from pharmacy rebates is reported as a reduction of claims expense in the statutory basis statements of income. Generally, rebate amounts are invoiced within fifteen days after each quarter-end and settled within 85 days of the invoice date. Pharmaceutical rebates billed but uncollected less than 90 days of invoice date have been admitted.
- 14. Claims overpayment receivables invoiced and expected to be collected within 90 days of invoice date have been admitted.
- 15. Effective January 1, 2015, the Company adopted SSAP No. 106, Affordable Care Act Assessments, for the annual health insurance industry fee imposed under Section 9010 of the Affordable Care Act. Refer to Note 22 for additional information about this fee and the estimated financial impact to the Company.

D. Going Concern

Based on management's evaluation, the Company does not have any doubts in its ability to continue as a going concern.

- 2. Accounting Changes and Corrections of Errors
 - A. Material Changes in Accounting Principles and/or Correction of Errors

Changes in Accounting Principles – not applicable

Corrections of Errors – not applicable

- 3. Business Combinations and Goodwill
 - A. Statutory Purchase Method not applicable.
 - B. Statutory Merger not applicable.
 - C. Assumption Reinsurance not applicable.
 - D. Impairment Loss not applicable.
- 4. Discontinued Operations
 - 1. Identity of Segment Discontinued not applicable.
 - 2. Expected Disposal Date not applicable.
 - 3. Expected Manner of Disposal not applicable.
 - 4. Description of Remaining Assets and Liabilities not applicable.
 - 5. Amounts Related to Discontinued Operations not applicable.
- 5. Investments
 - A. Mortgage Loans, including Mezzanine Real Estate Loans not applicable.

NOTES TO FINANCIAL STATEMENTS

- B. Debt Restructuring not applicable.
- C. Reverse Mortgages not applicable.
- D. Loan-Backed Securities
 - 1. Prepayment assumptions for loan-backed securities and other structured securities were obtained from external financial data sources. These assumptions are consistent with the current interest rate and economic environment.
 - 2. As of December 31, 2015, there are no loan-backed securities or structured securities with a recognized other-than-temporary impairment.
 - 3. During the twelve months ended December 31, 2015, there were no loan-backed or structured securities with a recognized other-than-temporary impairment.
 - 4. As of December 31, 2015, loan-backed and structured securities with a decline in fair value from amortized cost were as follows, including the length of time of such decline.
 - a. The aggregate amount of unrealized losses:

Less than 12 months: \$377
 12 months or longer: \$ -

b. The aggregate related fair value of securities with unrealized losses:

Less than 12 months: \$ 84,269
 12 months or longer: \$ -

- 5. Management reviews loan-backed and other structured securities with a decline in fair value from cost for impairment based on criteria that include:
 - length of time and severity of decline;
 - financial and specific near term prospects of the issuer;
 - changes in the regulatory, economic or general market environment of the issuer's industry or geographic region; and
 - the Company's intent to sell or the inability or lack of intent to retain the investment in the security for a period of time sufficient to recover the amortized cost.
- E. Repurchase Agreements and/or Securities Lending Transactions not applicable.
- F. Real Estate not applicable.
- G. Investments in Low Income Housing Tax Credits not applicable.
- H. Restricted Assets
 - (1) Restricted Assets (Including Pledged)

The Company has restricted assets of \$8,046,466 and \$10,262,378 on deposit with various regulatory agencies for the projection or benefit of enrolled members at December 31, 2015 and 2014, respectively. These amounts are reflected as bonds in the accompanying Balance Sheets. The following table presents the restricted assets as a percentage of total gross assets and total admitted assets.

NOTES TO FINANCIAL STATEMENTS

a. Subject to contractual obligation for which liability is not shown b. Collateral held under security lending agreements c. Subject to repurchase agreements d. Subject to repurchase agreements e. Subject to reverse repurchase agreements e. Subject to dollar reverse repurchase agreements fr. Subject to dollar reverse repurchase agreements g. Placed under option contracts h. Letter stock or securities restricted as to sale i. FHLB capital stock j. On deposit with other regulatory bodies l. Pledged collateral to FHLB (including assets backing funding agreements) m. Pledged as collateral not captured in other categories n. Other restricted assets s. 8,046,466 s. 10,262,378 s. 2,215,912 s. 8,046,466 s. 1,3% s. 1,3% s. 0,148 estricted Assets s. 8,046,466 s. 10,262,378 s. 2,215,912 s. 8,046,466 s. 1,3% s. 1,3	Restricted Asset Category	Total Gross Restricted from Current Year	Total Gross Restricted from Prior Year	Increase (Decrease)	Total Current Year Admitted Restricted	Percentage Gross Restricted to Total Assets	Percentage Admitted Restricted to Total Admitted Assets
lending agreements c. Subject to repurchase agreements d. Subject to reverse repurchase agreements e. Subject to dollar repurchase agreements f. Subject to dollar repurchase agreements f. Subject to dollar reverse repurchase agreements g. Placed under option contracts h. Letter stock or securities restricted as to sale f. FHLB capital stock f. FHLB capital stock f. On deposit with states f. Subject to dollar reverse repurchase agreements g. Placed under option contracts f. Subject to dollar reverse repurchase agreements g. Placed under option contracts f. Letter stock or securities restricted as to sale f. FHLB capital stock f. FHLB capital stock f. FHLB capital stock f. FHLB capital stock f. On deposit with states f. Subject to dollar reverse frequencias f. FHLB capital stock f.		\$ -	\$ -	\$ -	\$ -	-	-
d. Subject to reverse repurchase agreements e. Subject to dollar repurchase agreements f. Subject to dollar reverse repurchase agreements g. Placed under option contracts h. Letter stock or securities restricted as to sale i. FHLB capital stock j. On deposit with other regulatory bodies l. Pledged collateral to FHLB (including assets backing funding agreements) g. Pledged as collateral not captured in other categories g. Pledged assets g. C.		-	-	-	-	-	-
e. Subject to dollar repurchase agreements	d. Subject to reverse repurchase	-	-	-	-	-	-
agreements f. Subject to dollar reverse repurchase agreements g. Placed under option contracts h. Letter stock or securities restricted as to sale i. FHLB capital stock j. On deposit with states k. On deposit with other regulatory bodies l. Pledged collateral to FHLB (including assets backing funding agreements) m. Pledged as collateral not captured in other categories n. Other restricted assets l. Other restricted assets	ě	-	-	-	-	-	-
g. Placed under option contracts h. Letter stock or securities restricted as to sale	agreements	-	-	-	-	-	-
h. Letter stock or securities restricted as to sale i. FHLB capital stock - j. On deposit with states 8,046,466 10,262,378 (2,215,912) 8,046,466 1.3% 1.3% k. On deposit with other regulatory bodies - l. Pledged collateral to FHLB (including assets backing funding agreements) m. Pledged as collateral not captured in other categories n. Other restricted assets - l. Pledged assets - l. Pledged as collateral not captured in other categories - l. Pledged assets - l.		-	-	-	-	-	-
j. On deposit with states 8,046,466 10,262,378 (2,215,912) 8,046,466 1.3% 1.3% k. On deposit with other regulatory bodies	h. Letter stock or securities	-	-	-	-	-	-
k. On deposit with other regulatory bodies	i. FHLB capital stock	-	-	-	-	-	-
bodies	j. On deposit with states	8,046,466	10,262,378	(2,215,912)	8,046,466	1.3%	1.3%
(including assets backing funding agreements)		-	-	-	-	-	-
in other categories	(including assets backing funding agreements)	-	-	-	-	-	-
	in other categories	- -	-	-	- -	- -	- -
	o. Total Restricted Assets	\$ 8,046,466	\$ 10,262,378	\$ (2,215,912)	\$ 8,046,466	1.3%	1.3%

- (2) Detail of Assets Pledged as Collateral Not Captured in Other Categories (Contracts that Share Similar Characteristics, Such as Reinsurance and Derivatives, Are Reported in the Aggregate) not applicable
- (3) Detail of Other Restricted Assets (Contracts that Share Similar Characteristics, Such as Reinsurance and Derivatives, are Reported in the Aggregate) not applicable
- I. Investments for Working Capital Finance Investments none
- J. Offsetting and Netting of Assets and Liabilities none
- K. Structured Notes none
- 6. Joint Ventures, Partnerships and Limited Liability Companies
 - A. Investments in Joint Ventures, Partnerships and Limited Liability Companies not applicable.
 - B. Impaired Investments in Joint Ventures, Partnerships and Limited Liability Companies not applicable.

7. Investment Income

- A. Any investment income due and accrued with amounts that are over 90 days past due are nonadmitted and excluded from surplus.
- B. As of December 31, 2015 and 2014, the Company had no investment income due and accrued with admitted amounts that are over 90 days past due.
- 8. Derivative Instruments
 - A. Market Risk, Credit Risk, and Cash Requirements for Derivatives not applicable.
 - B. Objectives for the Use of Derivatives not applicable.
 - C. Description of Accounting Policies for Derivatives not applicable.

D&E. Net Gain or Loss from Derivatives – not applicable.

F. Cash Flow Hedges – not applicable.

9. **Income Taxes**

- A. The components of the net deferred tax asset/(liability) at December 31 are as follows:
 - 1. Components of net admitted deferred tax assets.

_	December 31, 2015							
_	Ordinary		(Capital		Total		
	\$	9,862,031	\$	163,142	\$	10,025,173		
(b) Statutory valuation allowance adj.		_		-		_		
(c) Adjusted gross DTA (1a - 1b)		9,862,031		163,142		10,025,173		
(d) DTA nonadmitted		436,676		163,142		599,818		
(e) Subtotal net admitted DTA (1c - 1d)		9,425,355		-		9,425,355		
(f) DTL		165,278		-		165,278		
(g) Net admtted DTA/(DTL) (1e - 1f)	\$	9,260,077	\$	-	\$	9,260,077		

	December 31, 2014						
	Ordinary		Capital			Total	
(a) Gross DTA	\$	19,056,540	\$	- \$	5	19,056,540	
(b) Statutory valuation allowance adj.		=		-			
(c) Adjusted gross DTA (1a - 1b)		19,056,540		-		19,056,540	
(d) DTA nonadmitted		642,595		-		642,595	
(e) Subtotal net admitted DTA (1c - 1d)		18,413,945		-		18,413,945	
(f) DTL		89,956		-		89,956	
(g) Net admtted DTA/(DTL) (1e - 1f)	\$	18,323,989	\$	- \$	5	18,323,989	

	Change					
		Ordinary	-	Capital		Total
(a) Gross DTA	\$	(9,194,509)	\$	163,142	\$	(9,031,367)
(b) Statutory valuation allowance adj.		-		-		-
(c) Adjusted gross DTA (1a - 1b)		(9,194,509)		163,142		(9,031,367)
(d) DTA nonadmitted		(205,919)		163,142		(42,777)
(e) Subtotal net admitted DTA (1c - 1d)		(8,988,590)		=		(8,988,590)
(f) DTL		75,322		_		75,322
(g) Net admtted DTA/(DTL) (1e - 1f)	\$	(9.063.912)	\$	_	\$	(9.063.912)

(b) Statutory variation and wante aug.			
(c) Adjusted gross DTA (1a - 1b)	19,056,540	-	1
(d) DTA nonadmitted	642,595	-	
(e) Subtotal net admitted DTA (1c - 1d)	18,413,945	-	1
(f) DTL	89,956	-	
(g) Net admtted DTA/(DTL) (1e - 1f)	\$ 18,323,989	\$ -	\$ 1
		Change	
	Ordinary	Capital	7
(a) Gross DTA	\$ (9,194,509)	\$ 163,142	\$ (
(b) Statutory valuation allowance adj.	 (0.104.500)	162 142	
(c) Adjusted gross DTA (1a - 1b)	(9,194,509)	163,142	(
(d) DTA nonadmitted	 (205,919)	163,142	
(e) Subtotal net admitted DTA (1c - 1d)	(8,988,590)	-	(
(f) DTL	 75,322	_	
(g) Net admtted DTA/(DTL) (1e - 1f)	\$ (9,063,912)	\$ _	\$ (

2. Admission Calculation Components of SSAP No. 101

	December 31, 2015				
	(Ordinary		Capital	Total
(a) Federal income taxes paid in prior years recoverable through loss carrybacks (b) Admitted gross DTAs expected to be realized (excluding the amount of DTAs from 2(a) above)	\$	9,130,181	\$	- \$	9,130,181
after application of the threshold limitation. (The lesser of 2(b)1 and 2(b)2 below)		129,896		-	129,896
 Adjusted gross DTAs expected to be realized following the balance sheet date. Adjusted gross DTAs allowed per 		129,896		-	129,896
limitation threshold. (c) Adjusted gross DTAs (excluding the amount of		xxx		xxx	47,717,533
DTAs from 2(a) and 2(b) above) offset by gross DTLs (d) DTAs admitted as the result of application of		165,278		-	165,278
SSAP No. 101 Total $2(a) + 2(b) + 2(c)$	\$	9,425,355	\$	- \$	9,425,355
				nber 31, 2014	, ,
		Ordinary De	cen	Capital	Total
 (a) Federal income taxes paid in prior years recoverable through loss carrybacks (b) Admitted gross DTAs expected to be realized (excluding the amount of DTAs from 2(a) above) 	\$	18,174,277	\$	- \$	18,174,277
after application of the threshold limitation. (The lesser of 2(b)1 and 2(b)2 below) 1. Adjusted gross DTAs expected to be		149,712		-	149,712
realized following the balance sheet date. 2. Adjusted gross DTAs allowed per		149,712		-	149,712
limitation threshold. (c) Adjusted gross DTAs (excluding the amount of DTAs from 2(a) and 2(b) above) offset by		XXX		xxx	46,561,593
gross DTLs (d) DTAs admitted as the result of application of SSAP No. 101		89,956			89,956
Total $2(a) + 2(b) + 2(c)$	\$	18,413,945	\$	- \$	18,413,945
				Change	
		Ordinary		Capital	Total
 (a) Federal income taxes paid in prior years recoverable through loss carrybacks (b) Admitted gross DTAs expected to be realized (excluding the amount of DTAs from 2(a) above) 	\$	(9,044,096)	\$	- \$	(9,044,096)
after application of the threshold limitation. (The lesser of 2(b)1 and 2(b)2 below) 1. Adjusted gross DTAs expected to be		(19,816)		-	(19,816)
realized following the balance sheet date. 2. Adjusted gross DTAs allowed per		(19,816)		-	(19,816)
limitation threshold. (c) Adjusted gross DTAs (excluding the amount of		XXX		XXX	1,155,940
DTAs from 2(a) and 2(b) above) offset by gross DTLs (d) DTAs admitted as the result of application of		75,322		-	75,322
SSAP No. 101 Total $2(a) + 2(b) + 2(c)$	\$	(8,988,590)	\$	- \$	(8,988,590)
10th 2(h) + 2(b) + 2(b)	Ψ	(0,700,570)	Ψ	- ψ	(0,700,370)

3. Information for Recovery Period and Threshold Limitation

	2015	2014
(a) Ratio percentage used to determine recovery		
period and threshold limitation amount	447%	486%
(b) Amount of adjusted capital and surplus used		
to determine recovery period and threshold	\$ 318,116,887 \$	310,410,620

- 4. Impact of Tax-Planning Strategies not applicable.
- B. Regarding Deferred Tax Liabilities that are not recognized:

All deferred tax liabilities have been properly recognized.

C. Current income taxes incurred consist of the following major components:

	December 31,					
		2015		2014		Change
1. Current Income Toylog						
 Current Income Taxes: (a) Federal 	\$	23,249,251	\$	23,867,183	\$	(617.022)
(b) Foreign	Ф	23,249,231	Ф	23,007,103	Ф	(617,932)
(c) Subtotal		23,249,251		23,867,183		(617,932)
(d) Federal income tax on net capital gains		47,025		484,362		(437,337)
(e) Utilization of capital loss carry-forwards		- 77,023		-0-1,502		(437,337)
(f) Other		_		_		_
(g) Federal and foreign income taxes incurred	\$	23,296,276	\$	24,351,545	\$	(1,055,269)
2. Deferred Tax Assets:						
(a) Ordinary:						
(1) Discounting of unpaid losses	\$	449,933	\$	444,789	\$	5,144
(2) Unearned premium reserve		464		9,564		(9,100)
(3) Policyholder reserves		-		-		-
(4) Investments		2,849		2,216		633
(5) Deferred acquisition costs		-		-		-
(6) Policyholder dividends accrual		-		-		-
(7) Fixed assets		-		-		-
(8) Compensation and benefits accrual		-		-		-
(9) Pension accrual		-		-		-
(10) Receivables - nonadmitted		2,910,857		1,027,044		1,883,813
(11) Net operating loss carry-forward		-		-		-
(12) Tax credit carry-forward		-		-		-
(13) Other		-		-		-
(14) Deferred gain related to intangibles		1,035,591		1,188,920		(153,329)
(15) Allowance for doubtful accounts		218,492		554,397		(335,905)
(16) Premium deficiency reserve	_	5,243,845		15,829,610		(10,585,765)
(99) Subtotal	\$	9,862,031	\$	19,056,540	\$	(9,194,509)
(b) Statutory valuation allowance adjustment		-		_		_
(c) Nonadmitted		436,676		642,595		(205,919)
(d) Admitted ordinary DTAs (2a99 - 2b - 2c)		9,425,355		18,413,945		(8,988,590)
(e) Capital:						
(1) Investments		163,142		-		163,142
(2) Net capital loss carry-forward		-		-		-
(3) Real estate		-		_		-
(4) Other		-		-		-
(99) Subtotal	\$	163,142	\$	-	\$	163,142
(f) Statutory valuation allowance adjustment		-		-		-
(g) Nonadmitted		163,142		-		163,142
(h) Admitted capital DTAs (2a99 - 2f - 2g)	\$		\$	-	\$	
(i) Admitted DTAs (2d + 2h)	\$	9,425,355	\$	18,413,945	\$	(8,988,590)

December 31,					
	2015		2014		Change
\$	165,278	\$	89,956	\$	75,322
	-		-		-
	-		-		-
	-		-		-
	-		-		-
	-		-		-
	-		-		-
	-		-		-
	-		-		-
	_		-		
\$	165,278	\$	89,956	\$	75,322
\$	-	\$	-	\$	-
	-		-		-
	_				
\$	-	\$	-	\$	=
\$	165,278	\$	89,956	\$	75,322
\$	9,260,077	\$	18,323,989	\$	(9,063,912)
	\$ \$ \$	\$ 165,278	\$ 165,278 \$	\$ 165,278 \$ 89,956	\$ 165,278 \$ 89,956 \$

The change in net deferred income taxes is comprised of the following (this analysis is exclusive of nonadmitted deferred tax assets as the Change in Nonadmitted Assets is reported separately from the Change in Net Deferred Income Taxes in the surplus section of the Annual Statement):

	December 31,					
		2015		2014		Change
Total gross deferred tax assets	\$	10,025,173	\$	19,056,540	\$	(9,031,367)
Total deferred tax liabilities	-	165,278	-	89,956	-	75,322
Net deferred tax assets/(deferred tax liabilities)	\$	9,859,895	\$	18,966,584	\$	(9,106,689)
Statutory valuation allowance		-		-		=
Net DTA/(DTL) after SVA	\$	9,859,895	\$	18,966,584	\$	(9,106,689)
Tax effect of unrealized gains (losses)						(163,142)
Change in net deferred income tax					\$	(9,269,831)

D. Reconciliation of Federal Income Tax Rate to Actual Effective Rate

The provision for federal income taxes incurred is different from that which would be obtained by applying the statutory federal income tax rate to income before income taxes including realized capital gains and losses. The significant items causing this difference are as follows:

	December 31,		Effective Tax	
		2015	Rate	
Provision computed at statutory rate	\$	24,272,846	35.0%	
Change in nonadmitted assets		(1,883,813)	-2.7%	
Investment income		(50,726)	-0.1%	
Meals & entertainment		8,282	0.1%	
Health Insurance Industry Fee		10,692,834	15.4%	
Other, net		(473,316)	-0.7%	
Total	\$	32,566,107	47.0%	
Federal and foreign income taxes incurred	\$	23,296,276	33.6%	
Change in net deferred income taxes	Ф	9,269,831	13.4%	
Total statutory income taxes	•	32,566,107	47.0%	
Total Statutory income taxes	Φ	32,300,107	47.070	

- E. Operating Loss and Tax Credit Carry forwards
- (1) At December 31, 2015 the Company had utilized all its net operating or capital loss carry forwards.
- (2) The following are the income taxes incurred in the current and prior years that will be be available for recoupment in the event of future net losses:

	Year	Amount		
2015		\$ 23,295,015		
2014		\$ 24,351,545		

- (3) Deposits under IRS Code Section 6603 not applicable
- F. Consolidated Federal Income Tax Return
- (1) As of December 31, 2015, the following subsidiaries were included in the consolidated return:

Allegiance Benefit Plan Management, Inc.

Allegiance Cobra Services, Inc.

Allegiance Life & Health Insurance Company, Inc.

Allegiance Re, Inc.

Arizona Healthplan, Inc.

Benefit Management Corporation

Bravo Health Mid-Atlantic, Inc.

Bravo Health Pennsylvania, Inc.

CG Individual Tax Benefit Payments, Inc.

CG Life Pension Benefit Payments, Inc.

CG LINA Pension Benefit Payments, Inc.

Choicelinx Corporation

Cigna Arbor Life Insurance Company

Cigna Behavioral Health, Inc.

Cigna Behavioral Health of California, Inc.

Cigna Behavioral Health of Texas, Inc.

Cigna Benefits Financing, Inc.

Cigna Dental Health, Inc.

Cigna Dental Health of California, Inc.

Cigna Dental Health of Colorado, Inc.

Cigna Dental Health of Delaware, Inc.

Cigna Dental Health of Florida, Inc.

Cigna Dental Health of Illinois, Inc. Cigna Dental Health of Kansas, Inc.

Ciana Dantal Haalth of Kantasha Inc.

Cigna Dental Health of Kentucky, Inc.

Cigna Dental Health of Maryland, Inc.

Cigna Dental Health of Missouri, Inc.

Cigna Dental Health of New Jersey, Inc.

Cigna Dental Health of North Carolina, Inc.

Cigna Dental Health of Ohio, Inc.

Cigna Dental Health of Pennsylvania, Inc.

Cigna Dental Health of Texas, Inc.

Cigna Dental Health of Virginia, Inc. Cigna Dental Healthplan of Arizona, Inc.

Cigna Direct Marketing Company, Inc.

Cigna Federal Benefits, Inc.

Cigna Global Holdings, Inc.

Cigna Global Insurance Company Limited

Cigna Global Reinsurance Company LTD

Cigna Health and Life Insurance Company

Cigna Health Corporation

Cigna Health Management, Inc.

Cigna Healthcare Benefits, Inc.

Cigna Healthcare Holdings, Inc.

Cigna Healthcare, Inc.

Cigna Healthcare Mid-Atlantic, Inc.

Cigna Healthcare of Arizona, Inc.

Cigna Healthcare of California, Inc.

Cigna Healthcare of Colorado, Inc.

Cigna Healthcare of Connecticut, Inc.

Cigna Healthcare of Florida, Inc.

Cigna Healthcare of Georgia, Inc.

Cigna Healthcare of Illinois, Inc.

Cigna Healthcare of Indiana, Inc. Cigna Healthcare of Maine, Inc.

Cigna Healthcare of Massachusetts, Inc.

Cigna Healthcare of New Hampshire, Inc.

Cigna Healthcare of New Jersey, Inc.

Cigna Healthcare of New York, Inc.

Cigna Healthcare of North Carolina, Inc.

Cigna Healthcare of Pennsylvania, Inc.

Cigna Healthcare of South Carolina, Inc.

Cigna Healthcare of St Louis, Inc.

Cigna Healthcare of Tennessee, Inc.

Cigna Healthcare of Texas, Inc.

Cigna Healthcare of Utah, Inc.

Cigna Holdings, Inc.

Cigna Holdings Overseas, Inc.

Cigna Integrated Care, Inc.

Cigna Intellectual Property, Inc.

Cigna International Corporation

Cigna International Finance, Inc.

Cigna International Services, Inc.

Cigna Investment Group, Inc.

Cigna Investments, Inc.

Cigna Life Insurance Company of New York

Cigna Linden Holdings, Inc.

Cigna Managed Care Benefits Company

Cigna Mezzanine Partners, III, Inc.

Cigna Poplar Holdings, Inc.

Cigna RE Corporation

Cigna Resource Manager, Inc.

Cigna Worldwide Insurance Company

Connecticut General Benefit Payments, Inc.

Connecticut General Corporation

Connecticut General Life Insurance Company

Former Cigna Investments, Inc.

GreatWest Healthcare of Illinois, Inc.

Hazard Center Investment Co., LLC

Healthsource Benefits, Inc.

Healthsource, Inc.

Healthsource Properties, Inc.

HealthSpring Life & Health Insurance Company, Inc.

HealthSpring Management, Inc.

HealthSpring of Alabama, Inc.

HealthSpring of Florida, Inc.

HealthSpring of Tennessee, Inc.

HealthSpring, Inc.

IHN, Inc.

Intermountain Underwriters, Inc.

Kronos Optimal Health Company

Life Ins Co of North America

LINA Benefit Payments, Inc.

Managed Care Consultants, Inc.
MCC Independent Practice Assoc of New York, Inc.

Mediversal Inc.

QualCare Alliance Networks, Inc.

QualCare Captive Insurance Company, Inc.

QualCare Management Resources LLC

QualCare, Inc.

Scibal Associates, Inc.

Sagamore Health Network Inc.

Tel-Drug, Inc.

Universal Claims Administration

NOTES TO FINANCIAL STATEMENTS

- (2) As of February 1, 2012, the Company entered into a Consolidated Federal Income Tax Agreement (the "Agreement") with Cigna and its domestic subsidiaries. Pursuant to the Agreement, federal income taxes are allocated to the Company as if it were filing on a separate return basis. The tax benefit of net operating losses, capital losses and tax credits are funded to the extent they reduce the consolidated federal income tax liability.
- (3) CIGNA's federal income tax returns are routinely audited by the Internal Revenue Service (IRS). In management's opinion, adequate tax liabilities, including related charges should the IRS prevail, have been established to address potential exposures involving tax positions the Company has taken that may be challenged by the IRS. These liabilities could be revised in the near term if estimates of CIGNA's ultimate liability change as a result of new developments or a change in circumstances.
- (4) The The IRS began its examination of the 2011 and 2012 tax years in the third quarter of 2014 and is expected to continue through 2016.
- G. Federal or Foreign Income Tax Loss Contingencies

In management's opinion, adequate tax liabilities have been established to address potential exposures involving tax positions the Company has taken that may be challenged by the IRS.

10. Information Concerning Parent, Subsidiaries and Affiliates

A. B. and C.

As of December 31, 2015 and 2014, the Company paid \$32,500,000 and \$57,400,000, respectively, in ordinary dividends to NewQuest, LLC (the Parent). No capital contributions were received in 2015 or 2014.

The Company has entered into a line of credit agreement with Cigna under which the Company may lend up to \$30,000,000. The Company did not loan any funds to Cigna during 2015 and 2014.

The Company has entered into a line of credit agreement with Cigna Holdings, Inc. under which the Company may borrow up to \$30,000,000. As of December 31, 2015 and 2014, there was no outstanding payable balance to Cigna Holdings, Inc. In 2015 and 2014, the interest rate on loan amounts was an average yearly rate of 0.3478% and 0.2692%, respectively, and interest expense was \$2,322 and \$3,593, respectively.

- D. At December 31, 2015 and 2014, the Company reported \$74,050,177 and \$45,466,945, respectively, as the net amounts due to the parent, subsidiaries and affiliates. These amounts are settled periodically, usually monthly.
- E. Guarantees Resulting in a Material Contingent Exposure not applicable.
- F. Management Services Agreement

Fee Sharing Agreement (the Agreement) - Several of Cigna's subsidiaries are subject to the Health Insurance Providers Fee, "the Fee", which is imposed on each covered entity engaged in the business of providing health insurance for any United States health risk. Such entities, along with Cigna, are collectively treated as a single "covered entity" as that term is defined in Section 9010(c) and Treas. Reg. § 57.2(b). By entering into this Agreement, each Party has consented to select Cigna as its "designated entity" for the payment of this Fee. The Agreement allows Cigna to pay each year to the Treasury the Fee owed collectively by all covered entities in the group, and to perform all necessary and appropriate actions that may be required to fulfill Cigna's responsibilities as the designated entity. This Agreement further allows Cigna to delegate to a wholly owned subsidiary the authority to perform these actions on Cigna's behalf. For financial management and reporting purposes, Cigna and the Parties will allocate the Fee for each Fee Year among the Parties in proportion to estimates of each Party's Premiums for that Fee Year. This Agreement was submitted for Department approval/non-disapproval, and is effective for HealthSpring Life and Health Insurance Company, Inc. on August 11, 2014.

The Company has contracted for managerial, administrative, and financial support services through an administrative service contract based on a percentage of premium revenue with HealthSpring Management of America, LLC (HSMA). For the years ended December 31,

NOTES TO FINANCIAL STATEMENTS

2015 and 2014, the Company paid approximately \$283,417,838 and \$263,791,097, respectively, in exchange for these services.

The Company has contracted with HSMA to provide disease management services related to the implementation and operation of the Internal Disease Management Program. For the years ended December 31, 2015 and 2014, the Company paid approximately \$20,674,944 and \$22,672,330, respectively.

The Company has contracted with Cigna Investment, Inc. (CII) for investment advisory services. The Company and CII are indirect subsidiaries of Cigna Holdings, Inc., which is a direct wholly-owned subsidiary of Cigna. The Company paid \$424,502 and \$385,278 in 2015 and 2014, respectively, for these services.

Cigna's indirectly wholly-owned domestic subsidiary insurance companies have entered into a Consolidated Federal Income Tax Agreement (the Agreement), which became effective as of April 1, 1982. The Agreement sets forth the method of allocation of federal income taxes for Cigna and its wholly-owned domestic subsidiaries, including insurance subsidiaries. The Agreement provides for immediate reimbursement to companies with net operating losses to the extent that their losses are used to reduce consolidated taxable income; while those companies with current taxable income as calculated under federal separate return provisions, are liable for payment determined as if they had each filed a separate return. However, current credit is given for any foreign tax credit, operating loss or investment tax credit carryovers actually used in the current consolidated return. The Company participates as a party to the agreement and had \$2,958,102 and \$16,353,714 recoverable under the agreement as of December 31, 2015 and 2014, respectively.

The Company is a party to an Expense Sharing Agreement between Cigna and various affiliates and subsidiaries. With the exception of a limited number of expenses held at the corporate level such as expenses relating to investments, the servicing of debt, and stock compensation as calculated under SFAS No. 123R, all operating expenses of Cigna were allocated. These allocations were based on work effort studies and other appropriate methods, while other expenses such as outside legal fees were directly charged to the related company. Cigna did not allocate any corporate overhead expenses to the Company in 2015 or 2014.

The Company, CII and certain of its affiliates are parties to an investment pool agreement which provides for participation in a pool of short-term investments to facilitate effective cash management. There are no fees separately assessed related to this agreement.

G. Ownership

All outstanding shares of the Company are owned by NewQuest, LLC, a limited liability company domiciled in the state of Texas, which is a wholly owned subsidiary of HealthSpring, Inc., a Delaware corporation, which is an indirect wholly-owned subsidiary of Cigna. The Cigna organizational structure is documented in Schedule Y.

- H. Upstream Intermediate Entity not applicable.
- I. Investment in SCA Entity that Exceeds 10% of Admitted Assets not applicable.
- J. Investments in Impaired SCA's not applicable.
- K. Investments in Foreign Insurance Subsidiaries not applicable.
- L. Investment in a Downstream Non-Insurance Holding Company not applicable.

11. Debt

A. Debt and Capital Notes

The Company had no capital notes outstanding at December 31, 2015 and 2014.

The Company had no external borrowed money outstanding at December 31, 2015 and 2014.

The Company has entered into a line of credit agreement with Cigna Holdings, Inc. under which the Company may borrow up to \$30,000,000. As of December 31, 2015 and 2014, there was no outstanding payable balance to Cigna Holdings, Inc. In 2015 and 2014, the

NOTES TO FINANCIAL STATEMENTS

interest rate on loan amounts was an average yearly rate of 0.3478% and 0.2692%, respectively, and interest expense was \$2,322 and \$3,593, respectively.

- B. FHLB Agreements not applicable.
- 12. Retirement Plans, Deferred Compensation, Post-Employment Benefits and Compensated Absences and Other Postretirement Benefit Plans
 - A. Defined Benefit Plan not applicable.
 - B. Investment Policies and Strategies for Plan Assets not applicable.
 - C. Fair Value Measurement of Plan Assets not applicable.
 - D. Rate of Return on Plan Assets not applicable.
 - E. Defined Contribution Plan not applicable.
 - F. Multi-Employer Plan not applicable.
 - G. Consolidated/Holding Company Plans not applicable.
 - H. Postemployment Benefits and Compensated Absences not applicable.
 - I. Impact of Medicare Modernization Act on Postretirement Benefits not applicable.
- 13. Capital and Surplus, Shareholders' Dividend Restrictions and Quasi-Reorganizations
 - 1. The Company has 5,000,000 shares authorized, 2,500,000 shares issued and outstanding of \$1 par value Common Stock, owned entirely by NewQuest, LLC.
 - 2. The Company has no preferred stock outstanding.
 - 3. The payment of dividends by the Company to the shareholder is limited and can only be made from earned profits unless prior approval is received from the Department. The maximum amount of dividends that may be paid by insurance companies without prior approval is also subject to restrictions relating to statutory surplus and net income. The maximum ordinary dividend distribution allowed by the Company in 2016 is \$46,054,710. The Company's dividends are noncumulative.
 - 4. The Company paid ordinary dividends of \$32,500,000 and \$57,400,000 in 2015 and 2014, respectively, to its Parent.
 - 5. Within the limits of (3) above, there are no restrictions placed on the portion of Company profits that may be paid as ordinary dividends to stockholders.
 - 6. Restrictions on Unassigned Surplus none.
 - 7. For Mutual Companies, Advances to Surplus Not Repaid not applicable.
 - 8. Stock Held by the Company, Including Stock of Affiliated Companies not applicable.
 - 9. Special Surplus Funds The change in special surplus funds is the recognition of the 2015 Health Insurance Industry Fee of \$30,531,093.
 - 10. Cumulative Unrealized Gains and Losses in Surplus

Unassigned surplus at December 31, 2015 was reduced by cumulative net unrealized investment losses of \$302,977. There was no net unrealized investment impact at December 31, 2014.

- 11. Surplus Note none.
- 12. Quasi-Reorganization not applicable.
- 13. Date of a Quasi Reorganization not applicable.
- 14. Liabilities, Contingencies and Assessments

NOTES TO FINANCIAL STATEMENTS

- A. Contingent Commitments none.
- B. Assessments none.
- C. Gain Contingencies none.
- D. Claims-Related Extra Contractual Obligations none.
- E. Joint and Several Liabilities none.
- F. All Other Liabilities:

Litigation and Other Legal Matters:

Cigna Corporation and its subsidiaries (including the Company; and collectively known as Cigna Corporation) are routinely involved in numerous claims, lawsuits, regulatory audits, investigations and other legal matters arising, for the most part, in the ordinary course of managing a health services business. These actions may include benefit disputes, breach of contract claims, tort claims, provider disputes, disputes regarding reinsurance arrangements, employment and employment discrimination-related suits, employee benefit claims, wage and hour claims, privacy, intellectual property claims and real estate related disputes. There are currently, and may be in the future, attempts to bring class action lawsuits against the industry. Cigna Corporation and its subsidiaries (including the Company) also are regularly engaged in IRS audits and may be subject to examinations by various state and foreign taxing authorities. Disputed income tax matters arising from these examinations, including those resulting in litigation, are accounted for under the NAIC's accounting guidance for tax loss contingencies. Further information on income tax matters can be found in Note 9.

The business of administering and insuring health services programs, particularly health care and group insurance programs, is heavily regulated by federal and state laws and administrative agencies, such as state departments of insurance and the U.S. Departments of Health and Human Services, Treasury, Labor and Justice, as well as the courts. Health care regulation and legislation in its various forms, including the implementation of Health Care Reform, other regulatory reform initiatives, such as those relating to Medicare programs, or additional changes in existing laws or regulations or their interpretations, could have a material adverse effect on the Company's business, results of operations and financial condition.

In addition, there is heightened review by federal and state regulators of the health care, disability and life insurance industry business and related reporting practices. Cigna and its subsidiaries (including the Company) are frequently the subject of regulatory market conduct reviews and other examinations of its business and reporting practices, audits and investigations by state insurance and health and welfare departments, state attorneys general, CMS and the Office of Inspector General ("OIG"). With respect to Cigna's Medicare Advantage business, CMS and OIG perform audits to determine a health plan's compliance with federal regulations and contractual obligations, including compliance with proper coding practices (sometimes referred to as Risk Adjustment Data Validation audits or RADV audits), that may result in retrospective adjustments to payments made to health plans. Regulatory actions can result in assessments, civil or criminal fines or penalties or other sanctions, including loss of licensing or exclusion from participating in government programs.

Regulation, legislation and judicial decisions have resulted in changes to industry and Cigna and its subsidiaries' (including the Company) business practices, financial liability or other sanctions and will continue to do so in the future.

When the Cigna Corporation and its subsidiaries (including the Company) (in the course of its regular review of pending litigation and legal or regulatory matters) have determined that a material loss is reasonably possible, the matter is disclosed. In accordance with statutory accounting principles, when litigation and regulatory matters present loss contingencies that are both probable and estimable, the Company accrues the estimated loss by a charge to income. The amount accrued represents the Company's best estimate of the probable loss at the time. If only a range of estimated losses can be determined, the Company accrues an amount within the range that, in the Company's judgment, reflects the most likely outcome; if none of the estimates within that range is a better estimate than any other amount, the Company accrues the minimum amount of the range. In cases when the Company has accrued an estimated loss, the accrued amount may differ materially from the ultimate amount of the loss. In many proceedings, it is inherently difficult to determine whether any loss is probable or even possible or to estimate the amount or range of any loss. The Company provides

NOTES TO FINANCIAL STATEMENTS

disclosure in the aggregate for material pending litigation and legal or regulatory matters, including accruals, range of loss, or a statement that such information cannot be estimated. As a litigation or regulatory matter develops, the Company monitors the matter for further developments that could affect the amount previously accrued, if any, and updates such amount accrued or disclosures previously provided as appropriate.

The outcome of litigation and other legal or regulatory matters is always uncertain and unfavorable outcomes that are not justified by the evidence or existing law can occur. Cigna Corporation and its subsidiaries (including the Company) believe that it has valid defenses to the matters pending against it and is defending itself vigorously. The Company believes that the legal actions, regulatory matters, proceedings and investigations currently pending against it should not have a material adverse effect on the Company's results of operation, financial condition or liquidity based upon current knowledge and taking into consideration current accruals. Due to numerous uncertain factors presented in these cases, it is not possible to estimate an aggregate range of loss (if any) for these matters at this time. In light of the uncertainties involved in these matters, there is no assurance that their ultimate resolution will not exceed the amounts currently accrued by the Company. An adverse outcome in one or more of these matters could be material to the Company's results of operations, financial condition or liquidity for any particular period.

In April 2004, Cigna Corporation (of which, the Company is a subsidiary) was sued in a number of putative nationwide class actions alleging that Cigna Corporation improperly underpaid claims for out-of-network providers through the use of data provided by Ingenix, Inc., a subsidiary of one of the Cigna Corporation's competitors. These actions were consolidated into *Franco v. Connecticut General Life Insurance Company, et al.*, pending in the U.S. District Court for the District of New Jersey. The consolidated amended complaint, filed in 2009 on behalf of subscribers, health care providers and various medical associations, asserted claims related to benefits and disclosure under ERISA, the Racketeer Influenced and Corrupt Organizations (RICO) Act, the Sherman Antitrust Act and New Jersey state law and seeks recovery for alleged underpayments from 1998 through the present. Other major health insurers have been the subject of, or have settled, similar litigation.

In September 2011, the District Court (1) dismissed all claims by the health care provider and medical association plaintiffs for lack of standing; and (2) dismissed the antitrust claims, the New Jersey state law claims and the ERISA disclosure claim. In January 2013 and again in April 2014, the District Court denied separate motions by the plaintiffs to certify a nationwide class of subscriber plaintiffs. The Third Circuit denied plaintiff's request for an immediate appeal of the January 2013 ruling. As a result, the case is proceeding on behalf of the named plaintiffs only. In June 2014, the District Court granted Cigna Corporation's motion for summary judgment to terminate all claims, and denied the plaintiffs' partial motion for summary judgment. In July 2014, the plaintiffs appealed all of the District Court's decisions in favor of Cigna Corporation, including the class certification decision, to the Third Circuit. Cigna Corporation will continue to vigorously defend its position.

Following announcement of Cigna's merger agreement with Anthem as discussed in Note 1, six putative class action complaints (collectively complaints) were filed by purported Cigna shareholders on behalf of a purported class of Cigna shareholders. Five of the complaints were filed in the Court of Chancery of the State of Delaware. The sixth complaint was filed in the Connecticut Superior Court, Judicial District of Hartford. Additional lawsuits arising out of or relating to the merger agreement or the merger may be filed in the future.

Cigna, members of the Cigna board of directors, Anthem and Anthem Merger Sub Corp ("Merger Sub") have been named as defendants. The plaintiffs generally assert that the members of the Cigna board of directors breached their fiduciary duties to the Cigna shareholders during merger negotiations and by entering into the merger agreement and approving the merger, and that Cigna, Anthem and Merger Sub aided and abetted such breaches of fiduciary duties. The allegations include, among other things, that (1) the merger consideration undervalues Cigna, (2) the sales process leading up to the merger was flawed due to purported conflicts of interest of members of the Cigna board of directors and (3) certain provisions of the merger agreement inappropriately favor Anthem and inhibit competing bids. Plaintiffs seek, among other things, injunctive relief enjoining the merger, rescission of the merger agreement to the extent already implemented, and costs and damages.

Effective November 24, 2015, solely to avoid the costs, risks and uncertainties inherent in litigation, and without admitting any liability or wrongdoing, Cigna, Cigna's directors, Anthem and Merger Sub entered into a Memorandum of Understanding (MOU) to settle the Cigna Merger Litigation. Subject to court approval and further definitive documentation in a settlement agreement that will be subject to customary conditions, the MOU resolved the Cigna Merger Litigation and provided that Cigna would make certain additional disclosures related to the merger. If the Court approves the settlement, the Cigna Merger Litigation will

NOTES TO FINANCIAL STATEMENTS

be dismissed with prejudice and all claims that were or could have been brought in any actions challenging any aspect of the merger, the merger agreement and any related disclosures will be released. In connection with the settlement, subject to the ultimate determination of the Court, plaintiffs' counsel may receive an award of reasonable fees. There can be no assurance that the parties will ultimately enter into a settlement agreement, or that the Court will approve the settlement even if the parties were to enter into such agreement. The MOU may terminate, if, among other reasons, the Court does not approve the settlement or the merger is not consummated for any reason. Following entry into the MOU, the five complaints filed in Delaware were voluntarily dismissed with prejudice.

Risk Adjustment Data Validation Audits:

In connection with CMS's continuing statutory obligation to review risk score coding practices by Medicare Advantage plans, CMS is conducting audits of Medicare Advantage plans for compliance by the plans and their providers with proper coding practices (sometimes referred to as Risk Adjustment Data Validation Audits or RADV Audits). On September 14, 2015, the Company was notified one of its Medicare Advantage contracts, H4513, was selected for a Calendar Year (CY) 2012 Contract-Level Risk Adjustment Data Validation (RADV) audit.

In February 2012, CMS released a notice of final payment error calculation methodology for Medicare Advantage RADV audits. Among other matters, the notice provided that (i) CMS would perform its next round of Medicare Advantage contract-level audits on payment year 2011; (ii) payment year 2011 is the first year that CMS will conduct payment recovery based on extrapolated estimates; (iii) CMS expects to audit about 30 Medicare Advantage contracts each year; and (iv) payment recovery amounts will be subject to a fee-for-service adjuster that accounts for the fact that the documentation standard used in RADV audits to determine a contract's payment error is different from the documentation standard used to develop the Part C risk-adjustment model.

The Company is currently assessing the payment error calculation methodology and awaiting further guidance from CMS regarding, among other matters, the application of a Fee For Service Adjuster to the audit recovery amounts. Because of the ongoing uncertainty, the Company remains unable to reasonably estimate the probability of CMS's assertion of a claim for recoupment of overpaid premiums or the amount of loss, or range of potential losses, associated with RADV Audits. Accordingly, the Company has not made an accrual related thereto.

Health Care Regulation: As a managed care organization, the Company's operations are and will continue to be subject to pervasive federal, state, and local government regulation, which will have a material impact on our operations. The laws and regulations affecting our industry give state and federal regulatory authorities broad discretion in their exercise of supervisory, regulatory, and administrative powers. These laws and regulations are intended primarily for the benefit of members of and providers to the Company.

Health care regulation in its various forms could have an adverse effect on Company's health care operations if it inhibits the Company's ability to respond to market demands or results in increased medical or administrative costs without improving the quality of care or services.

- E. Uncollectible Amounts none
- 15. Leases
 - A. Lessee Operating Leases none
 - B. Lessor Leases none
- 16. Information About Financial Instruments With Off-Balance Sheet Risk and Financial Instruments With Concentrations of Credit Risk
 - 1. Financial Instruments with Off-Balance Sheet Risk not applicable.
 - 2. Nature and Terms of Financial Instruments with Off-Balance Sheet Risk not applicable.
 - 3. Amount of Loss not applicable.
 - 4. Policy for Requiring Collateral not applicable.

NOTES TO FINANCIAL STATEMENTS

- 17. Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities
 - A. Transfer of Receivables Reported as Sales not applicable.
 - B. Transfer and Servicing of Financial Assets not applicable.
 - C. Wash Sales none.
- 18. Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans
 - A. ASO Plans not applicable.
 - B. ASC Plans not applicable.
 - C. Medicare or Similarly Structured Cost Based Reimbursement Contracts not applicable.
- Direct Premium Written/Produced by Managing General Agents/Third Party Administrators
 Not applicable.
- 20. Fair Value Measurements

The Company's financial assets measured at fair value include bonds valued at the lower of cost or fair value when reported at fair value at the balance sheet date.

Fair value is defined as the price at which an asset could be exchanged in an orderly transaction between market participants at the balance sheet date. The Company's financial assets have been classified based upon a hierarchy defined by SAP. The hierarchy gives the highest ranking to fair values determined using unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest ranking to fair values determined using methodologies and models with unobservable inputs (Level 3). An asset's or a liability's classification is based on the lowest level input that is significant to its measurement. For example, a financial asset or liability carried at fair value would be classified in Level 3 if unobservable inputs were significant to the instrument's fair value, even though the measurement may be derived using inputs that are both observable (Levels 1 and 2) and unobservable (Level 3).

The Company estimates fair values using prices from third parties or internal pricing methods. Fair value estimates received from third-party pricing services are based on reported trade activity and quoted market prices when available, and other market information that a market participant may use to estimate fair value. The internal pricing methods are performed by the Company's investment professionals and generally involve using discounted cash flow analyses, incorporating current market inputs for similar financial instruments with comparable terms and credit quality, as well as other qualitative factors. In instances where there is little or no market activity for the same or similar instruments, the fair value is estimated using methods, models, and assumptions that the Company believes a hypothetical market participant would use to determine a current transaction price. These valuation techniques involve some level of estimation and judgment that becomes significant with increasingly complex instruments or pricing models.

Fair Value Measurements at Reporting Date

The following table provides information about the Company's financial assets carried at fair value as of December 31, 2015. The Company had no bonds reported at fair value in the financial statements as of December 31, 2014.

December 31, 2015				
	Quoted Prices in Active Markets for Identical Assets		Significant Unobservable Inputs	
Financial Assets at Fair Value	(Level 1)	(Level 2)	(Level 3)	Total
Bonds - Industrial and miscellaneous	\$ -	\$ 3,146,502	\$ -	\$ 3,146,502

Level 1 Financial Assets

Inputs for instruments classified in Level 1 include unadjusted quoted prices for identical assets in active markets accessible at the measurement date. Active markets provide pricing data for trades occurring at least weekly and include exchanges and dealer markets.

NOTES TO FINANCIAL STATEMENTS

Level 2 Financial Assets

Inputs for instruments classified in Level 2 include quoted prices for similar assets in active markets, quoted prices from those willing to trade in markets that are not active, or other inputs that are market observable or can be corroborated by market data for the term of the instrument. Such other inputs include market interest rates and volatilities, spreads and yield curves. An instrument is classified in Level 2 if the Company determines that unobservable inputs are insignificant. Level 2 assets primarily include corporate bonds valued using recent trades of similar securities or pricing models that discount future cash flows at estimated market interest rates.

Level 3 Financial Assets

Certain inputs for instruments classified in Level 3 are unobservable (supported by little or no market activity) and significant to their resulting fair value measurement. Unobservable inputs reflect the Company's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date.

Fair Value Measurements at Reporting Date

Disclosures about Fair Values of Financial Instruments Not Carried at Fair Value

The following tables provide the fair value, carrying value and classification in the fair value hierarchy of the Company's bonds not recorded at fair value as of December 31, 2015 and 2014.

Decemb	er 31, 2015					
	Aggregate Fair Value	Admitted Assets	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Not Practicable (Carrying Value)
Bonds	\$ 302,607,591	\$ 303,800,475	\$ 7,370,684	\$289,109,367	\$ 6,127,540	\$ -
Decemb	er 31, 2014					
			Quoted Prices in Active Markets for Identical Assets	Significant Other Observable	Significant Unobservable	
	Aggregate Fair Value	Admitted Assets	(Level 1)	Inputs (Level 2)	Inputs (Level 3)	Not Practicable (Carrying Value)
Bonds	\$ 276,529,077	\$ 273,829,942	\$ 9,582,345	\$260,413,053	\$ 6,533,229	\$ -

Disclosures about Financial Instruments Not Practicable to Estimate Fair Value – None.

21. Other Items

- A. Extraordinary Items none.
- B. Troubled Debt Restructuring: Debtors none.
- C. Other Disclosures and Unusual Items none
- D. Business Interruption Insurance Recoveries none.
- E. State Transferable and Non-transferable Tax Credits none.
- F. Subprime Mortgage-Related Risk Exposure
 - 1. The Company did not hold mortgage loans in 2015 and 2014 and, therefore, is not subject to the related risk exposure pertaining to subprime mortgages.
 - 2. Direct Exposure through Investments in Subprime Loans not applicable.
 - 3. Direct Exposure through Other Investments not applicable.
 - 4. Underwriting Exposure to Subprime Mortgage Risk not applicable.

G. Retained Assets - none

22. Events Subsequent

NOTES TO FINANCIAL STATEMENTS

The Company is not aware of any Type I events that occurred subsequent to the close of the books or accounts for this statement which would have a material effect on the financial condition of the Company. In preparing these financial statements, the Company evaluated events that occurred between the balance sheet date and February 27, 2016 for the statutory statement filed on February 27, 2016.

On February 19, 2016, CMS issued its Advance Notice of Methodological Changes for Calendar Year 2017 for Medicare Advantage Capitation Rates, Part C and Part D Payment Policies (the Notice). The final terms are expected to be published on April 4, 2016. While the terms contained within the Notice are within the range of our expectations, there remain numerous open issues and substantial uncertainties regarding the final terms of the Notice. We expect that CMS will receive a significant number of comments from interested parties (including Cigna) prior to issuing the final terms; however, there can be no assurance that CMS will amend its current positions. Given the uncertainty regarding the final terms of the Notice, we cannot reliably estimate the impact on our business, revenues or results of operations in 2017 and beyond; under certain circumstances, it is possible that the impact could be materially adverse. In addition, we expect to adjust our programs and services in response to the proposed 2017 terms.

Type II – Nonrecognized Subsequent Events:

Subsequent events have been considered through February 27, 2016 for the statutory statement issued on February 27, 2016.

In January 2016, CMS issued to Cigna a Notice of Imposition of Immediate Intermediate Sanctions ("the Notice"). The Notice requires Cigna to suspend certain enrollment and marketing activities for its Medicare Advantage Prescription Drug and Medicare Part D Plans. The sanctions do not impact the ability of current enrollees to remain covered by the Company's Medicare Advantage Prescription Drug or Medicare Part D Plans.

CMS imposed sanctions based on its finding of deficiencies with Cigna's operations of its Parts C and D appeals and grievances, Part D formulary and benefit administration, and compliance program. Cigna is working to resolve these matters as quickly as possible and is cooperating fully with CMS on its review. Based on management's current expectations, the Company does not expect the impact to its financial statements to be material.

On January 1, 2016, the Company will be subject to an annual fee under section 9010 of the Federal Affordable Care Act (ACA). Cigna covered entities' share of the annual fee was based on the ratio of the amount of their aggregate net premiums written during the preceding calendar year to the amount of health insurance for any U.S. health risk that is written during the preceding year. A health insurance entity's portion of the annual fee becomes payable once the entity provides health insurance for any U.S. health risk for each calendar year beginning on or after January 1 of the year the fee is due. As of December 31, 2015, the Company has written health insurance subject to the ACA assessment, expects to conduct health insurance business in 2016, and estimates its portion of the annual health insurance industry fee payable on September 30, 2016 to be \$30,351,093. This amount is reflected in special surplus. This assessment is expected to impact risk based capital (RBC) by 43%. Reporting the ACA assessment as of December 31, 2015, would not have triggered an RBC action level.

	Current Year	Prior Year
A. Did the reporting entity write accident and health insurance premium that is subject to Section 9010 of the federal Affordable Care Act (Yes/No)?	Yes	Yes
B. ACA fee assessment payable for the upcoming year	\$ 30,351,093	\$ 29,286,730
C. ACA fee assessment paid	\$ 30,590,297	\$ 28,358,430
D. Premium written subject to ACA 9010 assessment	\$ 2,209,296,062	\$ 2,203,228,301
E. Total Adjusted Capital before surplus adjustmentF. Total Adjusted Capital after surplus adjustment (Five-	\$ 327,376,963	\$ 328,734,609
Year Historical Line 14 minus 22B above) G. Authorized Control Level after surplus adjustment (Five-	\$ 296,845,870	\$ 299,447,878
Year Historical Line 15) H. Would reporting the ACA assessment as of December 31,	\$ 71,221,970	\$ 63,920,259
2015, have triggered an RBC action level (Yes/No)?	No	No

23. Reinsurance

A. Ceded Reinsurance Report

NOTES TO FINANCIAL STATEMENTS

Section 1- General Interrogatories

- (1) Are any of the reinsurers, listed in Schedule S as non-affiliated, owned in excess of 10% or controlled, either directly or indirectly, by the Company or by any representative, officer, trustee or director of the Company?
 - Yes() No(X)
- (2) Have any policies issued by the Company been reinsured with a company chartered in a country other than the United States (excluding U.S. Branches of such companies) that is owned in excess of 10% or controlled directly or indirectly by an insured, a beneficiary, a creditor or any other person not primarily engaged in the insurance business?
 - Yes() No(X)

Section 2 – Ceded Reinsurance Report – Part A

- (1) Does the Company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than for nonpayment of premium or other similar credit?
 - Yes() No(X)
- (2) Does the reporting entity have any reinsurance agreements in effect such that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts that, in aggregate and allowing for offset of mutual credits from other reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsured policies?
 - Yes() No(X)

Section 3 – Ceded Reinsurance Report – Part B

- (1) What is the estimated amount of the aggregate reduction in surplus, (for agreements other than those under which the reinsurer may unilaterally cancel for reasons other than for nonpayment of premium or other similar credits that are reflected above) of termination of all reinsurance agreements, by either party, as of the date of this statement? Where necessary, the Company may consider the current or anticipated experience of the business reinsured in making this estimate. none.
- (2) Have any new agreements been executed or existing agreements amended, since January 1 of the year of this statement, to include policies or contracts that were in force or which had existing reserves established by the Company as of the effective date of the agreement?
 - Yes() No(X)
- B. Uncollectible Reinsurance none.
- C. Commutation of Ceded Reinsurance none.
- D. Certified Reinsurer Rating Downgraded or Status Subject to Revocation none
- 24. Retrospectively Rated Contracts and Contracts Subject to Redetermination
 - A. Method Used to Estimate Accrued Retrospective Premium Adjustments not applicable.
 - B. Where Accrued Retrospective Premium Adjustments are Recorded not applicable.
 - C. Amount of Net Written Premiums Subject to Retrospective Rating Features not applicable.
 - D. Medical loss ratio rebates required pursuant to the Public Health Service Act

On January 1, 2014, the Company became subject to the minimum loss ratio rebate provisions of the Patient Protection and Affordable Care Act (PPACA). PPACA require payment of premium rebates to customers covered under the Company's comprehensive medical insurance if certain annual minimum medical loss ratios are not met. At the close of each quarter, the Company records its rebate accrual based on year-to-date estimated medical loss ratios calculated as prescribed by the interim final rule issued by the Department of Health & Human Services using year-to-date premium and claim information by state and market segment. Since this accrual reflects the amount of rebate that would be payable based on year-to-date estimated medical loss ratios, the amount of rebate will fluctuate as actual claim experience develops each calendar quarter.

As of December 31, 2015, the Company accrued an estimated rebate of \$776,727 and no rebate balance as of December 31, 2014.

NOTES TO FINANCIAL STATEMENTS

				Large	Other	
			Small Group	Group	Categories	
		Individual	Emp loy er	Emp loy er	with Rebates	Total
Prio	Reporting Year					
(1)	Medical loss ratio rebates incurred	-	-	-	-	-
(2)	Medical loss ratio rebates paid	-	-	-	-	-
(3)	Medical loss ratio rebates unpaid	-	-	-	-	-
(4)	Plus reinsurance assumed amounts	XXX	XXX	XXX	XXX	
(5)	Less reinsurance ceded amounts	XXX	XXX	XXX	XXX	
(6)	Rebates unpaid net of reinsurance	XXX	XXX	XXX	XXX	
Curr	ent Reporting Year-to-date					
(7)	Medical loss ratio rebates incurred	-	-	-	776,727	776,727
(8)	Medical loss ratio rebates paid	-	-	-	-	-
(9)	Medical loss ratio rebates unpaid	-	-	-	776,727	776,727
(10)	Plus reinsurance assumed amounts	XXX	XXX	XXX	XXX	
(11)	Less reinsurance ceded amounts	XXX	XXX	XXX	XXX	
(12)	Rebates unpaid net of reinsurance	XXX	XXX	XXX	XXX	

E. Risk Sharing Provisions of the Affordable Care Act – the Company does not write business subject to the Risk Sharing Provisions of the Affordable Care Act.

25. Change in Incurred Claims and Claim Adjustment Expenses

The liability for claims unpaid as of December 31, 2014 was \$134,709,867. During 2015, \$94,815,860 has been paid on these liabilities. Reserves remaining for prior years are now \$5,908,587, as a result of re-estimation of unpaid claims and claim adjustment expenses. Therefore, there has been a favorable prior year development of \$33,985,420 since December 31, 2014. This release is generally the result of ongoing analysis of recent loss development trends. Original estimates are increased or decreased, as additional information becomes known regarding individual claims.

	U	Inpaid Claims	crued Medical centive Pool & Bonus	Healthcare Receivable	Total
12/31/2014 Balance	\$	134,709,867	\$ 9,702,137	\$ (93,311,519)	\$ 51,100,486
Paid/(Received)		94,815,860	3,485,625	(94,743,518)	3,557,966
Favorable/(Unfav) Development		33,985,420	4,076,167	6,771,962	44,833,549
12/31/2015 Balance for 2014 & Prior	\$	5,908,587	\$ 2,140,345	\$ (5,339,962)	\$ 2,708,970

26. Intercompany Pooling Arrangements

A.-G.-none

27. Structured Settlements Not applicable.

Health Care Receivables

A. Pharmaceutical Rebate Receivables

The Estimated Pharmacy Rebates as Reported on Financial Statements for December 31, 2015 and 2014.

ANNUAL STATEMENT FOR THE YEAR 2015 OF THE HealthSpring Life & Health Insurance Company, Inc. NOTES TO FINANCIAL STATEMENTS

					Actual
	Estimated		Actual	Actual	Rebates
	Pharmacy		Rebates	Rebates	Received
	Rebates as		Received	Received	Within More
	Reported on	Pharmacy	Within 90	Within 91 to	Than 180
	Financial	Rebates as	Days of	180 Days of	Days of
Quarter Ended	Statements	Billed	Billing	Billing	Billing
12/31/15	\$ 17.784.390	\$ 17.328.232	\$ -	\$ -	\$ -
	* ','- , '	4,,	*	5 -	\$ -
09/30/15	17,662,611	17,033,443	16,577,285	-	-
06/30/15	22,347,246	15,764,881	15,122,868	642,013	-
03/31/15	39,546,478	13,826,444	7,237,257	6,542,533	46,655
12/31/14	76,750,628	58,356,894	27,071,677	31,285,217	-
09/30/14	78,302,018	53,664,654	27,219,635	26,445,019	_
06/30/14	86,784,435	56,074,079	27,901,201	26,030,603	2,142,274
03/31/14	60,559,492	58,566,867	29,787,957	27,257,450	1,521,460
12/31/13	71,683,778	72,493,834	72,232,940	253,332	7,562
09/30/13	69,602,110	69,873,459	69,171,947	621,451	80,061
06/30/13	60,112,299	60,045,583	60,179,215	(150,047)	16,416
03/31/13	55,879,371	55,723,485	55,665,856	202,774	(145,146)

B. Risk Sharing Receivables

Calendar Year	Evaluation Period	Re as I	Risk Sharing sceivable Estimated the Prior Year	Re as l	Risk Sharing sceivable Estimated in the trent Year		sk Sharing eceivable Billed	Re N	Risk Sharing ceivable Not Yet Billed
2015	2015	\$	-	\$	-	\$	-	\$	-
	2016		XXX	\$	-		XXX		-
2014	2014	\$	786,961	\$	-	\$	1,991,986	\$	-
	2015		XXX	\$	-		XXX		-
2013	2013	\$	-	\$	-	\$	-	\$	-
	2014		XXX	\$	-		XXX		-
		S A	etual Risk Sharing mounts llected in	S	ctual Risk Sharing cceivable	1	ctual Risk Sharing Amounts Received	S	Actual Risk Sharing mounts
Calendaı	Evaluation		Year	Fi	irst Year		cond Year		ceived -
Year	Period	In	voiced	Su	bsequent	Sı	ıbsequent	A	ll Other
2015	2015 2016	\$	- xxx	\$	- xxx	\$	- xxx	\$	- xxx
2014	2014	\$ 1	1,991,986	\$	-	\$	-	\$	-
	2015		XXX		XXX	\$	-	\$	-
2013	2013	\$	-	\$	-	\$	-	\$	-
	2014		XXX		XXX		XXX		XXX

C. Other Healthcare Receivables

Other Healthcare receivables included \$2,152,557 in claim recoveries, \$119,034 related to plan to plan pharmacy settlements, \$4,381,056 recoverable from the State of Texas and \$388,977 related to other medical receivables.

28. Participating Policies

NOTES TO FINANCIAL STATEMENTS

None.

29. Premium Deficiency Reserves

Premium deficiencies occur when it is probable that expected claims expense (hospital/medical expenses and administrative expenses) will exceed future premiums on existing insurance contracts. For purposes of estimating premium deficiency losses, contracts are grouped in a manner consistent with the Company's method of acquiring, servicing, and measuring the profitability of such contracts. At December 31, 2015 and 2014, the Company had liabilities of \$14,982,414 and \$45,227,461, respectively, related to premium deficiency reserves on its Medicaid business.

1. Liability carried for premium deficiency reserves \$14,982,414 January 13, 2016 2. Date of the most recent evaluation of this liability

3. Was anticipated investment income utilized in the calculation?

No

30. Anticipated Salvage and Subrogation

None.

PART 1 - COMMON INTERROGATORIES GENERAL

1.1	Is the reporting entity a member of an Insurance Holding Company System of is an insurer?			Yes [X	1	No [1
	If yes, complete Schedule Y, Parts 1, 1A and 2			•	•		•
1.2	If yes, did the reporting entity register and file with its domiciliary State Insura such regulatory official of the state of domicile of the principal insurer in the providing disclosure substantially similar to the standards adopted by the Nits Model Insurance Holding Company System Regulatory Act and model resubject to standards and disclosure requirements substantially similar to the	Holding Company System, a registration statement lational Association of Insurance Commissioners (NAIC) in equilations pertaining thereto, or is the reporting entity	Yes [X]] No []	N/A	[]
1.3	State Regulating?			Texa	18		
2.1	Has any change been made during the year of this statement in the charter, reporting entity?			Yes []	No []	Х]
2.2	If yes, date of change:						
3.1	State as of what date the latest financial examination of the reporting entity w	was made or is being made		12/31/	2014	ŧ	
3.2	State the as of date that the latest financial examination report became avail entity. This date should be the date of the examined balance sheet and not			12/31/	2010)	
3.3	State as of what date the latest financial examination report became availabl domicile or the reporting entity. This is the release date or completion date examination (balance sheet date).	of the examination report and not the date of the		09/19/	2012	2	
3.4	By what department or departments? Texas Department of Insurance						
3.5	Have all financial statement adjustments within the latest financial examinati statement filed with Departments?	ion report been accounted for in a subsequent financial	Yes [X]] No []	N/A	[]
3.6	Have all of the recommendations within the latest financial examination repo	ort been complied with?	Yes [X]] No []	N/A	[]
4.1	4.12 renewals? During the period covered by this statement, did any sales/service organizati	of the reporting entity), receive credit or commissions for or ss measured on direct premiums) of: new business? ion owned in whole or in part by the reporting entity or an affi		Yes [Yes [
	receive credit or commissions for or control a substantial part (more than 20 premiums) of:						
		new business??		Yes [Yes [
5.1	Has the reporting entity been a party to a merger or consolidation during the	period covered by this statement?		Yes []	No []	Х]
5.2	If yes, provide the name of the entity, NAIC Company Code, and state of do ceased to exist as a result of the merger or consolidation.	omicile (use two letter state abbreviation) for any entity that ha	as				
	1 Name of Entity	2 3 NAIC Company Code State of Domicile					
6.1	Has the reporting entity had any Certificates of Authority, licenses or registra revoked by any governmental entity during the reporting period?			Yes []	No []	Х]
6.2	If yes, give full information:						
7.1	Does any foreign (non-United States) person or entity directly or indirectly co	ontrol 10% or more of the reporting entity?		Yes []	No []	Х]
7.2	If yes,						Q/
	7.21 State the percentage of foreign control;7.22 State the nationality(s) of the foreign person(s) or entity(s) or if the entity attorney-in-fact; and identify the type of entity(s) (e.g., individual, corpo	ty is a mutual or reciprocal, the nationality of its manager or	<u>-</u>				%
	1 Nationality	2 Type of Entity					

	Is the company a subsidiary of a bank holding company regulated by the fresponse to 8.1 is yes, please identify the name of the bank holding	company.				Yes []	No	[X]
	Is the company affiliated with one or more banks, thrifts or securities fill response to 8.3 is yes, please provide below the names and location regulatory services agency [i.e. the Federal Reserve Board (FRB), the Insurance Corporation (FDIC) and the Securities Exchange Commission	irms? n (city and state of the main office) of any affiliat ne Office of the Comptroller of the Currency (OC	es regulate C), the Fed	d by a fe	deral	Yes []	No	[X]
	1	2	3	4	5	6	٦		
	Affiliate Name	Location (City, State)	FRB	OCC	FDIC	_			
	What is the name and address of the independent certified public accepricewaterhouseCoopers, LLC, 150 3rd Ave. S, Suite 1400, Nashville	5	ne annual a	udit?					
	Has the insurer been granted any exemptions to the prohibited non-au requirements as allowed in Section 7H of the Annual Financial Repolaw or regulation?	udit services provided by the certified independe orting Model Regulation (Model Audit Rule), or su	ıbstantially	similar s	tate	Yes []	No	[X]
10.2	If the response to 10.1 is yes, provide information related to this exem								
	Has the insurer been granted any exemptions related to the other requallowed for in Section 18A of the Model Regulation, or substantially s	uirements of the Annual Financial Reporting Mossimilar state law or regulation?	del Regulat	ion as		Yes []	No	[X]
10.4	If the response to 10.3 is yes, provide information related to this exem	·							
10.5	Has the reporting entity established an Audit Committee in compliance					() No [1	N/	A []
	If the response to 10.5 is no or n/a, please explain	·			100 [7	.] [,		
11.	What is the name, address and affiliation (officer/employee of the reportirm) of the individual providing the statement of actuarial opinion/cer Gregory N. Malone, Appointed Actuary, Cigna Healthcare Reserving,	orting entity or actuary/consultant associated wit rtification?	h an actuar	ial consi	ulting				
12.1	Does the reporting entity own any securities of a real estate holding co	ompany or otherwise hold real estate indirectly?				Yes []	No I	[X]
	12.11 Name of real	estate holding company							
		rcels involved							
10.0		ljusted carrying value				\$			
12.2	If, yes provide explanation:								
13.	FOR UNITED STATES BRANCHES OF ALIEN REPORTING ENTIT								
13.1	What changes have been made during the year in the United States n	manager or the United States trustees of the rep	orting entity	?					
10.0	Does this statement contain all business transacted for the reporting e	positivi the combined Limited Chatan Dramah on violen				V [1	M.	r 1
	Have there been any changes made to any of the trust indentures duri	, ,					-	No I	
	If answer to (13.3) is yes, has the domiciliary or entry state approved the	• •					-		
	Are the senior officers (principal executive officer, principal financial of] NO [J	IN/	4 []
	similar functions) of the reporting entity subject to a code of ethics, w (a) Honest and ethical conduct, including the ethical handling of actual relationships;	hich includes the following standards?				Yes [)	(]	No	i]
	(b) Full, fair, accurate, timely and understandable disclosure in the per		entity;						
	(c) Compliance with applicable governmental laws, rules and regulation								
	(d) The prompt internal reporting of violations to an appropriate persor	n or persons identified in the code; and							
14.11	(e) Accountability for adherence to the code. If the response to 14.1 is No, please explain:								
440	Has the code of ethics for senior managers been amended?					Yes []	No	[X]
	If the response to 14.2 is yes, provide information related to amendment								
14.21	Have any provisions of the code of ethics been waived for any of the s					Yes [1	No	[X]

	Is the reporting entity the beneficiary of a SVO Bank List?					Yes [1 '	No [X	. 1
15.2	If the response to 15.1 is yes, indicate the bank of the Letter of Credit and describe	e American Bankers Association	(ABA) Routing Number	and the name of the issuing or confirm	ning	•	•	•	•
	1 American Bankers	2		3			4		7
		nfirming Bank Name		That Can Trigger the Letter of Credit			nouni		
			OF DIRECTOR						
16.	Is the purchase or sale of all investment thereof?					Yes [)	(] [No []
17.	Does the reporting entity keep a comple thereof?					Yes [)	(]	No []
18.	Has the reporting entity an established part of any of its officers, directors, trus					Yes [)	(] !	No []
		F	INANCIAL						
19.	Has this statement been prepared using Accounting Principles)?	a basis of accounting other than	Statutory Accounting Pr	inciples (e.g., Generally Accepted		Voc [)	v 1	No I	1
20.1	Total amount loaned during the year (inc								
	, , ,	•		20.12 To stockholders not officers					
				20.13 Trustees, supreme or grand (Fraternal Only)					
20.2	Total amount of loans outstanding at the	end of year (inclusive of Separate	e Accounts, exclusive of	f					
	policy loans):			20.21 To directors or other officers		\$			0
				20.22 To stockholders not officers 20.23 Trustees, supreme or grand					
				(Fraternal Only)		\$			
21.1	Were any assets reported in this statem obligation being reported in the statement	ent subject to a contractual obliga	tion to transfer to anothe	er party without the liability for such					
21.2	If yes, state the amount thereof at Decei			21.21 Rented from others		\$	י נ	NO [A	
	•	•		21.22 Borrowed from others		\$			
				21.23 Leased from others		\$			
00.1	Does this statement include payments for	or accomments as described in th	a Annual Ctatament Inc	21.24 Other		\$			
22.1	guaranty association assessments?	or assessments as described in th	e Annuai Statement ins			Yes [] [No [X]
22.2	If answer is yes:			2.21 Amount paid as losses or risk adj					
			22	2.22 Amount paid as expenses		\$			
23.1	Does the reporting entity report any amo	unts due from parent, subsidiarie	22 or affiliates on Page 2	2.23 Other amounts paid		\$ اعم∨	1 '		1
	If yes, indicate any amounts receivable f								
		IN	VESTMENT						
24.01	Were all the stocks, bonds and other se the actual possession of the reporting of					Yes []	X]	No []
24.02	If no, give full and complete information	•							
24.03	For security lending programs, provide a whether collateral is carried on or off-b.	description of the program includation alance sheet. (an alternative is to	ling value for collateral a reference Note 17 when	and amount of loaned securities, and					
24.04	Does the Company's security lending pr Instructions?				Yes [] No []	N/A [X]
24.05	If answer to 24.04 is yes, report amount	of collateral for conforming progra	ıms			\$			
24.06	If answer to 24.04 is no, report amount of	of collateral for other programs				\$			
24.07	Does your securities lending program re outset of the contract?	quire 102% (domestic securities)	and 105% (foreign secu	rities) from the counterparty at the	Yes [] No []	N/A [X]
24.08	Does the reporting entity non-admit whe	n the collateral received from the	counterparty falls below	100%?	Yes [] No []	N/A [Х]
24.09	Does the reporting entity or the reporting conduct securities lending?				Yes [] No []	N/A [X]

24.10	For the reporting entity's security lending program	n state the amount of t	he following as Dece	ember 31 of the current year	ear:	
	24.101 Total fair value of reinve	sted collateral assets r	eported on Schedule	DL, Parts 1 and 2		B
	24.102 Total book adjusted/carr	ying value of reinveste	d collateral assets re	ported on Schedule DL,	Parts 1 and 2	\$
	24.103 Total payable for securiti	es lending reported or	the liability page			§
25.1	Were any of the stocks, bonds or other assets of control of the reporting entity, or has the reporting force? (Exclude securities subject to Interrogate	ng entity sold or transfe	erred any assets sub	ject to a put option contr	act that is currently in	Yes [X] No [
25.2	If yes, state the amount thereof at December 31	of the current year:	25.21	Subject to repurchase ag	reements	\$
			25.22	Subject to reverse repure	hase agreements	.\$
					ase agreements	
					repurchase agreements	
					restricted as to sale - Stock	
			25.27 I	FHLB Capital Stock		\$
					ulatory bodies	
				an FHLB	ccluding collateral pledged to	_\$
			25.31 I	Pledged as collateral to F	FHLB - including assets nents	¢
			25.32	Other		.\$
25.3	For category (25.26) provide the following:					
	1 Nature of Restriction			2 Description		3 Amount
26.1	Does the reporting entity have any hedging trans	actions reported on So	chedule DB?			Yes [] No [X]
00.0						
26.2	If yes, has a comprehensive description of the he if no, attach a description with this statement.	edging program been r	nade available to the	domiciliary state?	Yes [J No [] N/A [
27.1	Were any preferred stocks or bonds owned as or issuer, convertible into equity?					Yes [] No [X
27.2	If yes, state the amount thereof at December 31	of the current year				\$
28.	Excluding items in Schedule E - Part 3 - Special offices, vaults or safety deposit boxes, were all custodial agreement with a qualified bank or tru Outsourcing of Critical Functions, Custodial or S	stocks, bonds and other	er securities, owned to note with Section 1. I	throughout the current ye II - General Examination	ar held pursuant to a Considerations. F.	Yes [X] No [
28.01	For agreements that comply with the requirement	ts of the NAIC Financi	al Condition Examine	ers Handbook, complete	the following:	
	1 Name of Custodian(s)			2 Custodian's Ad	ldress	
	JPMorgan Chase Bank, N.A.	Brooklyn,				
28.02	For all agreements that do not comply with the reand a complete explanation:	·				
	1 Name(s)		2 Location(s)		3 Complete Explanation	on(s)
	- Hamo(o)					
	Have there been any changes, including name c If yes, give full and complete information relating	=	an(s) identified in 28.	01 during the current yea	ır?	Yes [] No [X
	1 Old Custodian	2 New Cus	stodian	3 Date of Change	4 Reason	
28.05	Identify all investment advisors, brokers/dealers handle securities and have authority to make in			ealers that have access to	the investment accounts,	
	1 Control Bank 1 11	2			3	
	Central Registration Depository Number(s)	Name			Address	
		s, Inc	90	00 Cottage Grove Road, I	Bloomfield, CT 06002	

	1			2			р.	3
	CUSIP#			Name of Mutual Fund			Cai	ok/Adjusted rrying Value
	29.2999 - Total							0
3	For each mutual fund listed in the	he table above, complete the fo	ollowing s	schedule:				
		1		2		3 Amount of Mut	ual	4
						Fund's Book/Adju Carrying Valu	usted ie	D
	Name of Mutual Fu	und (from above table)		Name of Significant Mutual Fi		Attributable to Holding	the	Date of Valuation
	Provide the following informatio statement value for fair value.	n for all short-term and long-te	rm bonds	s and all preferred stocks. [Do not substitute am	3 Excess of Statement		
		n for all short-term and long-te	rm bonds	1 Statement (Admitted)	2	3 Excess of Statement over Fair Value (-), or Fair Value over		
				1 Statement (Admitted) Value		3 Excess of Statement over Fair Value (-), or	-	
	statement value for fair value.			Statement (Admitted) Value367,684,695	2 Fair Value	3 Excess of Statement over Fair Value (-), or Fair Value over Statement (+)(1, 192,886	-	
	statement value for fair value. 30.1 Bonds			1 Statement (Admitted) Value367,684,695	2 Fair Value366,491,809	3 Excess of Statement over Fair Value (-), or Fair Value over Statement (+)(1, 192,886)	
	30.1 Bonds	ds utilized in determining the fa	uir values	Statement (Admitted) Value	2 Fair Value366,491,809366,491,809	3 Excess of Statement over Fair Value (-), or Fair Value over Statement (+)(1,192,886)	
	30.1 Bonds	ds utilized in determining the fa	uir values	Statement (Admitted) Value	2 Fair Value366,491,809 366,491,809	3 Excess of Statement over Fair Value (-), or Fair Value over Statement (+)(1,192,886)	es [] No [
	30.1 Bonds	ds utilized in determining the fa d market prices	nir values	Statement (Admitted) Value	2 Fair Value366,491,809	3 Excess of Statement over Fair Value (-), or Fair Value over Statement (+))) Y	es [] No [es [] No [

OTHER

33.1	Amount of payments to trade associations, service organizations and statistical or rating bureaus, if any?		\$	0
33.2	List the name of the organization and the amount paid if any such payment represented 25% or more of the tot service organizations and statistical or rating bureaus during the period covered by this statement.	al payments to trade as	sociations,	
	1 Name	2 Amount Paid		
34.1	Amount of payments for legal expenses, if any?		\$	0
34.2	List the name of the firm and the amount paid if any such payment represented 25% or more of the total payment during the period covered by this statement.	ents for legal expenses		
	1 Name	2 Amount Paid		
35.1	Amount of payments for expenditures in connection with matters before legislative bodies, officers or department	ents of government, if ar	ıy?\$	0
35.2	List the name of the firm and the amount paid if any such payment represented 25% or more of the total payment connection with matters before legislative bodies, officers or departments of government during the period co			
	1 Name	2 Amount Paid		

PART 2 - HEALTH INTERROGATORIES

1.1 1.2	Does the reporting entity have any direct Medicare Supplement Insurance in for If yes, indicate premium earned on U.S. business only.			
1.3	What portion of Item (1.2) is not reported on the Medicare Supplement Insurance 1.31 Reason for excluding			
1.4	Indicate amount of earned premium attributable to Canadian and/or Other Alier	n not included in Item (1.2) above	\$	
1.5	Indicate total incurred claims on all Medicare Supplement Insurance.			
1.6	Individual policies:	Most current three years:		
		1.61 Total premium earned	\$	0
		1.62 Total incurred claims	\$	0
		1.63 Number of covered lives		0
		All years prior to most current three years:		
		1.64 Total premium earned		0
		1.65 Total incurred claims	\$	0
		1.66 Number of covered lives		0
1.7	Group policies:	Most current three years:		
		1.71 Total premium earned	\$	0
		1.72 Total incurred claims		
		1.73 Number of covered lives		0
		All years prior to most current three years:		
		1.74 Total premium earned		
		1.75 Total incurred claims		
		1.76 Number of covered lives		0
2.	Health Test:			
		1 2		
	2.1 Premium Numerator	2 200 206 062 2 203 228 301		
	2.2 Premium Penominator			
	2.3 Premium Ratio (2.1/2.2)			
	2.5 Reserve Denominator			
	2.6 Reserve Ratio (2.4/2.5)	1 000 1 000		
3.1	Has the reporting entity received any endowment or gift from contracting hospit returned when, as and if the earnings of the reporting entity permits?	iais, physicians, dentists, or others that is agreed will be	Yes []	No [X]
4.1	Have copies of all agreements stating the period and nature of hospitals', physi dependents been filed with the appropriate regulatory agency?	icians', and dentists' care offered to subscribers and	Yes [X]	No []
4.2	If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do the	ese agreements include additional benefits offered?	Yes []	No []
5.1	Does the reporting entity have stop-loss reinsurance?		Yes []	No [X]
5.2	If no, explain: Management has elected not to purchase stop-loss reinsurance based on histo	orical trends.		
5.3	Maximum retained risk (see instructions)	5.31 Comprehensive Medical	\$	0
		5.32 Medical Only	\$	0
		5.33 Medicare Supplement	\$	0
		5.34 Dental & Vision	\$	0
		5.35 Other Limited Benefit Plan	\$	0
		5.36 Other	\$	0
6.	Describe arrangement which the reporting entity may have to protect subscribe hold harmless provisions, conversion privileges with other carriers, agreement agreements: Contracts contain "hold-harmless" language.	its with providers to continue rendering services, and any other		
7.1	Does the reporting entity set up its claim liability for provider services on a servi	ice date basis?	Yes [X]	No []
7.2	If no, give details			
8.	Provide the following information regarding participating providers:	8.1 Number of providers at start of reporting year		17,399
		8.2 Number of providers at end of reporting year.		20,733
9.1	Does the reporting entity have business subject to premium rate guarantees?		Yes []	No [X]
9.2	If yes, direct premium earned:	9.21 Business with rate guarantees between 15-36 months	: \$	
J. <u>C</u>	700, and promium duried.	9.22 Business with rate guarantees over 36 months		

10.1	Does the reporting entity have Incentive Pool, Withhold or Bonus Arrangements in its	provider contracts?	Yes [X] No	0 []	
10.2	1 1	0.21 Maximum amount payable bonuses	\$ \$	(3,105,7	76)
11.1	Is the reporting entity organized as:	11.12 A Medical Group/Staff Model, 11.13 An Individual Practice Association (IPA), or, . 11.14 A Mixed Model (combination of above)?	Yes [Yes [Yes [] N	No [X] No [X] No [X]	
11.2 11.3 11.4 11.5 11.6	Is the reporting entity subject to Statutory Minimum Capital and Surplus Requirements If yes, show the name of the state requiring such minimum capital and surplus. If yes, show the amount required. Is this amount included as part of a contingency reserve in stockholder's equity? If the amount is calculated, show the calculation		Yes [X 		o [] Tex 1,700,00 o [X]	

12. List service areas in which reporting entity is licensed to operate:

is licensed to operate:						
1 Name of Service Area						
Alabama - Part D						
Alaska - Part D						
Arizona - Part D						
Arkansas - Part D						
California - Part D						
Colorado - Part D						
Connecticut - Part D						
Delaware - Part D						
District of Columbia - Part D						
Florida - Part D						
Georgia - Part D						
Hawaii - Part D						
Idaho - Part D						
Illinois - Part D						
Indiana - Part D						
Iowa - Part D						
Kansas - Part D						
Kentucky - Part D						
Louisiana - Part D						
Maine - Part D						
Maryland - Part D						
Massachusetts - Part D						
Michigan - Part D						
Minnesota - Part D						
Mississippi - Part D						
Missouri - Part D						
Montana - Part D						
Nebraska - Part D						
Nevada - Part D						
New Hampshire - Part D						
New Jersey - Part D						
New Mexico - Part D						
New York - Part D						
North Carolina - Part D						
North Dakota - Part D						
Ohio - Part D						
Oklahoma - Part D						
Oregon - Part D						
•						
Rhode Island - Part D						
South Carolina - Part D						
Tennessee - Part D						
Texas - Part D						
Utah - Part D						
Vermont - Part D						
Virginia - Part D						
Washington - Part D						
West Virginia - Part D						
Wisconsin - Part D						
Wyoming - Part D						
Catoosa, GA						
Dade, GA						
Walker, GA						
Anderson, TX						
Angelina, TX						
Bexar, TX						
Bowie, TX						
Brazoria, TX						
Cameron, TX						
Camp, TX						

1 Name of Service Area
Cass, TX
Chambers, TX
Collin, TX
Cooke, TX
Dallas, TX
Delta, TX
Duvall, TX
Ellis, TX
EI Paso, TXFannin, TX
Fort Bend, TX
Franklin , TX
Galveston, TX
Grayson, TX
Hardin, TX
Harris, TX
Harrison, TX Henderson, TX
Hidalgo, TX
Hood, TX
Hopkins, TX Houston, TX
Hunt, TX
Jasper, TX
Jefferson, TX
Jim Hogg, TX
Johnson, TX
Kaufman, TX
Lamar, TX
Marion, TX
Maverick, TX
McMullen , TX
Montague, TX
Morris, TX
Nacogdoches, TX
Navarro, TX
Nueces, TX
Orange , TX
Panola, TX
Polk, TX
Rains, TX
Red River, TX
Rusk, TX
Sabine, TX
San Augustine, TX
San Jacinto, TX
Smith, TX
Starr, TX
Tarrant, TX
Travis, TX
Trinity, TX
Tyler, TX
Upshur, TX
Walker, TX
Waller, TX
Webb, TX
Wise, TX
Wood, TX
Zapata, TX

13.1	Do you act as a custodian for health savings accounts?	Yes	3 [] N	lo [X	[]
13.2	If yes, please provide the amount of custodial funds held as of the reporting date.	.\$				
13.3	Do you act as an administrator for health savings accounts?	Yes	s [] N	lo [X	[]
13.4	If yes, please provide the balance of funds administered as of the reporting date.	\$				
	Are any of the captive affiliates reported on Schedule S, Part 3, authorized reinsurers?] 1	No []	N/A	[X]

14.2 If the answer to 14.1 is yes, please provide the following:

1	2	3	4	Assets	Supporting Reserv	e Credit
	NAIC			5	6	7
	Company	Domiciliary	Reserve	Letters of	Trust	
Company Name	Code	Jurisdiction	Credit	Credit	Agreements	Other

15. Provide the following for individual ordinary life insurance* policies (U.S. business only) for the current year (prior to reinsurance assumed or ceded):

15.1 Direct Premium Written	\$ 0
15.2 Total Incurred Claims	\$ 0
15.3 Number of Covered Lives	0

10.11	
*Ordinary Life Insurance Includes	
Term(whether full underwriting, limited underwriting, jet issue, "short form app")	
Whole Life (whether full underwriting, limited underwriting, jet issue, "short form app")	
Variable Life (with or without secondary gurarantee)	
Universal Life (with or without secondary gurarantee)	
Variable Universal Life (with or without secondary gurarantee)	

FIVE-YEAR HISTORICAL DATA

	114	1	2	3	4	5
		2015	2014	2013	2012	2011
	Balance Sheet (Pages 2 and 3)					
1.	Total admitted assets (Page 2, Line 28)					
2.	Total liabilities (Page 3, Line 24)					
3.	Statutory minimum capital and surplus requirement		1,700,000		1,700,000	
4.	Total capital and surplus (Page 3, Line 33)	327,376,963	328,734,609	384,734,967	439,318,956	317,502,279
	Income Statement (Page 4)					
5.	Total revenues (Line 8)	2,213,499,831	2,205,421,691	2, 124, 314, 637	2,167,787,015	2,066,085,119
6.	Total medical and hospital expenses (Line 18)	1,815,181,348	1,823,249,406	1,737,091,020	1,711,096,177	1,657,566,392
7.	Claims adjustment expenses (Line 20)	143,828,585	140,299,062	68,277,164	84,215,413	80,679,576
8.	Total administrative expenses (Line 21)	223,274,842	192,290,949	205,581,871	183,561,772	164,710,434
9.	Net underwriting gain (loss) (Line 24)	61,460,103	13,562,421	104, 156,973	189,116,342	161,501,389
10.	Net investment gain (loss) (Line 27)	8,451,012	10,043,997	5,968,440	4, 137, 501	3,118,228
11.	Total other income (Lines 28 plus 29)	(607, 154)	(6,325,295)	(16,162,584)	(11,307,022)	(365,721
12.	Net income or (loss) (Line 32)	46,054,710	(6,586,059)	57,404,471	118,002,056	104,972,710
	Cash Flow (Page 6)					
13.	Net cash from operations (Line 11)	103,716,862	(175,616,476)	(13,871,086)	381,847,876	76,597,203
	Risk-Based Capital Analysis					
14.	Total adjusted capital	327,376,963	328,734,609	384,734,967	439,318,956	317,502,379
15.	Authorized control level risk-based capital	71,221,971	63,834,514	53, 103, 177	50,264,854	55,939,749
	Enrollment (Exhibit 1)					
16.	Total members at end of period (Column 5, Line 7)	166,636	511,731	592,201	741,913	942,567
17.	Total members months (Column 6, Line 7)	1,959,109	6,328,529	7,226,846	9,023,887	11,062,577
	Operating Percentage (Page 4) (Item divided by Page 4, sum of Lines 2, 3 and 5) x 100.0					
18.	Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5)	100.0	100.0	100.0	100.0	100.0
19.	Total hospital and medical plus other non-health (Lines 18 plus Line 19)	82.2	82.8	81.7	78.9	80.0
20.	Cost containment expenses	5.9	5.9	2.7		2.2
21.	Other claims adjustment expenses	0.6	0.5	0.5	0.3	1.7
22.	Total underwriting deductions (Line 23)	97.4	99.5	95.0	91.3	93.2
23.	Total underwriting gain (loss) (Line 24)	2.8	0.6	4.9	8.7	7.8
	Unpaid Claims Analysis (U&I Exhibit, Part 2B)					
24.	Total claims incurred for prior years (Line 13, Col. 5)	7,698,936	76,884,319	75 , 166 , 005	30,330,793	24 , 436 , 444
25.	Estimated liability of unpaid claims-[prior year (Line 13, Col. 6)]	51, 100, 486	96,143,766	97,415,922	44,267,950	23,358,615
	Investments In Parent, Subsidiaries and Affiliates					
26.	Affiliated bonds (Sch. D Summary, Line 12, Col. 1)					0
27.	Affiliated preferred stocks (Sch. D Summary, Line 18, Col. 1)					
28.	Affiliated common stocks (Sch. D Summary, Line 24, Col. 1)					
29.	Affiliated short-term investments (subtotal included in Schedule DA Verification, Col. 5, Line 10)	0	0	0	0	
30.	Affiliated mortgage loans on real estate					
31.	All other affiliated					
32.	Total of above Lines 26 to 31	0	0	0	0	c
33.	Total investment in parent included in Lines 26 to 31 above.					

NOTE: If	f a party to a merger, have the two most recent years of this exhibit been restated due to a merger in compliance with the disclosure			
	requirements of SSAP No. 3, Accounting Changes and Correction of Errors?	Yes [] No []
If	f no, please explain:			

SCHEDULE T PREMIUMS AND OTHER CONSIDERATIONS

Allocated by States and Territories

Allocated by States and Territories											
		1	2	3	4	5 Federal Employees	siness Only 6	7	8	9	
	States, etc.	Active Status	Accident & Health Premiums	Medicare Title XVIII	Medicaid Title XIX	Health Benefits Plan Premiums	Life & Annuity Premiums & Other Considerations	Property/ Casualty Premiums	Total Columns 2 Through 7	Deposit-Type Contracts	
1.	Alabama AL	L	81, 161	THE XVIII	THE XIX	1 Territariis	Considerations	1 Territariis	81, 161	Contracts	
2.	Alaska AK	L	15,026						15,026		
	Arizona AZ	L	34,341						34,341		
	Arkansas AR	<u>L</u>	23,238	15,610,037					15,633,274		
	California CA Colorado CO	L	58,841 5,600						58,841 5,600		
	Connecticut CT	 -	5,600						5,862		
	Delaware DE	L	9,469						9,469		
9.	District of Columbia DC	Ĺ	12,769						12,769		
	Florida FL	L	6,330						6,330		
11.	Georgia GA	ļĻ	10,066	24,747,216					24,757,282		
	Hawaii HI	L	11,305 21,845						11,305 21,845		
	Illinois	I	279,618						279,618		
	Indiana IN	Ĺ	12,385						12,385		
	lowa IA	L	4 , 108						4, 108		
	Kansas KS	L	6,736						6,736		
	Kentucky KY Louisiana LA	L	9,607 75,990				 		9,607 75,990		
	Maine ME	L	2,062		L				2,062	<u></u>	
	Maryland MD		52,490						52,490		
	Massachusetts MA	L	12,582						12,582	ļ	
	Michigan MI		29,852						29,852		
24. 25.	Minnesota MN	<u>-</u>	5,533 67,761						5,533 67,761		
	Mississippi MS Missouri MO	I	9,345						9,345		
27.	Montana MT	<u>_</u>	1,746						1,746		
28.	Nebraska NE	L	2, 157						2, 157		
	Nevada NV	L	7,285						7,285		
	New Hampshire NH	ļĻ	1,603						1,603 6,284		
	New Jersey NJ New Mexico NM	<u>-</u>	6,284 1,164						1,164		
	New York NY	L	262,886						262,886		
	North Carolina NC	L	7 , 187						7, 187		
	North Dakota ND	L	1,161						1, 161		
	Ohio OH	L	11,310						11,310		
	Oklahoma OK Oregon OR	L	12,076 42,457						,		
	Pennsylvania PA	L	67,937						07,007		
40.	Rhode Island RI	L	1,726						1 700		
	South Carolina SC	L	10,209						, .		
	South Dakota SD	L	1, 180						1,180		
	Tennessee TN Texas TX		109,779 317,993	1,341,219,894	825,835,340				109,779 2,167,373,228		
	Utah UT	I	18, 128	1,341,219,694	023,033,340				18,128		
	VermontVT		1,451						1,451		
	Virginia VA	L	10,786						10,786	ļ	
	Washington WA	L	93,569						93,569		
	West Virginia WV Wisconsin WI	L	19,398 9,529						19,398 9,529		
	Wyoming WY	L	9,529	L	L				9,529	<u></u>	
	American Samoa AS	N							0		
	Guam GU	N							0	ļ	
	Puerto Rico PR	NN							0		
	U.S. Virgin Islands VI Northern Mariana	N							0		
	Islands MP	N							0		
	Canada CAN	N					ļ		0	 	
58.	Aggregate other alien OT	XXX	0	0	0	n	0	0	0	0	
59.	Subtotal	XXX		1,381,577,147	825,835,340	0	0		2,209,296,062	0	
60.	Reporting entity contributions for Employee								0		
61.	Benefit Plans Total (Direct Business)	(a) 51	1,883,575	1,381,577,147	825,835,340	0	0	0	2,209,296,062	0	
	DETAILS OF WRITE-INS		, -,	, ,- ,	,,		1		, , , , , , , , , , , , ,	İ	
58001.		XXX					 				
58002.		XXX					 			 	
58003. 58998.	Summary of remaining	XXX					t		-		
33000.	write-ins for Line 58 from										
E0000	overflow page	XXX	0	0	0	0	0	0	0	0	
58999.	Totals (Lines 58001 through 58003 plus 58998)(Line 58	1									
<u> </u>	above)	XXX	0	0	0	0	0	0	0	0	
	sed or Chartered - Licensed Ins	urana Carriar	or Dominilad DDC	2: (R) Registered	- Non-domiciled	BBGs: (O) Quali	ified - Ouglified or	Accredited Dai			

⁽L) Licensed or Chartered - Licensed Insurance Carrier or Domiciled RRG; (R) Registered - Non-domiciled RRGs; (Q) Qualified - Qualified or Accredited Reinsurer; (E) Eligible - Reporting Entities eligible or approved to write Surplus Lines in the state; (N) None of the above - Not allowed to write business in the state.

Explanation of basis of allocation by states, premiums by state, etc.

Part D premiums are allocated based on prior year MMR data by state.

(a) Insert the number of L responses except for Canada and Other Alien.

SCHEDULE Y

PART 1 – ORGANIZATIONAL CHART

The following is a listing identifying and indicating the interrelationships among all affiliated insurers (identified by an asterisk, and if such insurer is incorporated in the United States of America, by a Federal Employer Identification Number, NAIC Company Code and Jurisdiction of Incorporation) and all other affiliates, as of December 31, 2015:

```
<u>Cigna CORPORATION</u>
(A Delaware corporation and ultimate parent company)
Cigna Holdings, Inc.
         Cigna Intellectual Property, Inc.
         Cigna Investment Group, Inc.
               Cigna International Finance Inc.
               Former Cigna Investments, Inc.
               Cigna Investments, Inc.
                       Cigna Mezzanine Partners III, Inc.
                               Cigna Mezzanine Partners III, LP
                       Cigna Benefits Financing, Inc.
(EI # 010947889, DE)
       Connecticut General Corporation
               Benefit Management Corp. (ET # 81-0585518)
                       *Allegiance Life & Health Insurance Company (EI # 20-4433475, NAIC # 12814, MT)
                       *Allegiance Re, Inc. (EI # 20-3851464, MT)
                        Allegiance Benefit Plan Management, Inc.
                        Allegiance COBRA Services, Inc.
                        Allegiance Provider Direct, LLC
                        Community Health Network, LLC
                        Intermountain Underwriters, Inc.
                        Star Point, LLC
              HealthSpring, Inc.
                       NewQuest, LLC
                               NewQuest Management Northeast, LLC
                                        *Bravo Health Mid-Atlantic, Inc. (EI # 52-2259087, NAIC # 10095, MD)
                                         Bravo Health Pennsylvania, Inc.
EI # 52-2363406, NAIC # 11254, PA)
                                  *HealthSpring Life & Health Insurance Company
(EI # 20-8534298, NAIC # 12902, TX)
                                  *HealthSpring of Alabama, Inc.
(EI # 63-0925225, NAIC # 95781, AL)
                                   HealthSpring of Florida, Inc.
EI # 65-1129599, NAIC #11532, FL)
                                  NewQuest Management of Illinois, LLC
                                  NewQuest Management of Florida, LLC
                                  HealthSpring Management of America, LLC
                                  NewQuest Management of West Virginia, LLC
                                  TexQuest, LLC
                                 HouQuest, LLC
                                       GulfQuest, LP
                                  NewQuest Management of Alabama, LLC
                                  HealthSpring USA, LLC
                                  HealthSpring Management, Inc.
                                       HealthSpring of Tennessee, Inc.
(EI # 62-1593150, NAIC # 11522, MD)
                                       | Tennessee Quest, LLC
                                  HealthSpring Pharmacy Services, LLC
                                       |HealthSpring Pharmacy of Tennessee, LLC
                                  Home Physicians Management, LLC
                *Cigna Arbor Life Insurance Company (EI # 03-0452349, NAIC # 13733, CT)
               Cigna Behavioral Health, Inc.
                       Cigna Behavioral Health of California, Inc. (EI# 94-3107309)
```

 $\frac{\text{Cigna Behavioral Health of Texas, Inc.}}{(\text{EI\# 75-2751090})}$ MCC Independent Practice Association of New York, Inc. Cigna Dental Health, Inc. Cigna Dental Health of California, Inc. (EI# 59-2600475, CA) Cigna Dental Health of Colorado, Inc. (EI# 59-2675861, NAIC # 11175, CO) Cigna Dental Health of Delaware, Inc. (EI# 59-2676987, NAIC # 95380, DE) Cigna Dental Health of Florida, Inc. (EI# 59-1611217, NAIC # 52021, FL) Cigna Dental Health of Illinois, Inc. (EI# 06-1351097, IL) Cigna Dental Health of Kansas, Inc. (EI# 59-2625350, NAIC # 52024, KS) Cigna Dental Health of Kentucky, Inc. (EI# 59-2619589, NAIC # 52108, KY) Cigna Dental Health of Missouri, Inc. (ET#06-1582068, NAIC # 11160, MO) Cigna Dental Health of New Jersey, Inc. (EI# 59-2308062, NAIC # 11167, NJ) Cigna Dental Health of North Carolina, Inc. (EI# 56-1803464 , NAIC # 95179, NC) Cigna Dental Health of Ohio, Inc. (EI# 59-2579774, NAIC # 47805, OH) Cigna Dental Health of Pennsylvania, Inc. (EI# 52-1220578, NAIC # 47041, PA) Cigna Dental Health of Texas, Inc. (EI# 59-2676977, NAIC # 95037, TX) Cigna Dental Health of Virginia, Inc. (EI# 52-2188914, NAIC # 52617, VA) Cigna Dental Health Plan of Arizona, Inc. (EI# 86-0807222, NAIC # 47013, AZ) Cigna Dental Health of Maryland, Inc. (EI#20-2844020, NAIC #48119, MD) Cigna Health Corporation Healthsource, Inc. Cigna HealthCare of Arizona, Inc. (EI# 86-0334392, NAIC#95125, AZ) Cigna HealthCare of California, Inc. (EI# 95-3310115, CA) Cigna HealthCare of Colorado, Inc. (EI# 84-1004500, NAIC # 95604, CO) Cigna HealthCare of Connecticut, Inc. (EI# 06-1141174, NAIC # 95660, CT) Cigna HealthCare of Florida, Inc. (EI# 59-2089259, NAIC # 95136, FL) Cigna HealthCare of Illinois, Inc. (EI# 36-3385638, NAIC # 95602, IL) Cigna HealthCare of Maine, Inc. (EI# 01-0418220, NAIC # 95447, ME) Cigna HealthCare of Massachusetts, Inc. (EI# 02-0402111, NAIC # 95220, MA) Cigna HealthCare Mid-Atlantic, Inc. (EI# 52-1404350, NAIC # 95599, MD) Cigna HealthCare of New Hampshire, Inc. (EI# 02-0387749, NAIC # 95493, NH) Cigna HealthCare of New Jersey, Inc. (EI# 22-2720890, NAIC # 95500, NJ) Cigna HealthCare of Pennsylvania, Inc. (EI# 23-2301807, NAIC # 95121, PA) Cigna HealthCare of St. Louis, Inc. (EI# 36-3359925, NAIC # 95635, MO) Cigna HealthCare of Utah, Inc. (EI# 62-1230908, NAIC # 95518, UT) Cigna HealthCare of Georgia, Inc. (EI# 58-1641057, NAIC # 96229, GA) Cigna HealthCare of Texas, Inc. (EI# 74-2767437, NAIC # 95383, TX) Cigna HealthCare of Indiana, Inc. (EI# 35-1679172, NAIC # 95525, IN)

```
Cigna HealthCare of Tennessee, Inc. (EI# 62-1218053, NAIC # 95606, TN)
                 Cigna HealthCare of North Carolina, Inc. (EI# 56-1479515, NAIC# 95132, NC)
                 Cigna HealthCare of South Carolina, Inc. (EI# 06-1185590, NAIC # 95708, SC)
                 *_{\hbox{\footnotesize Temple Insurance Company Limited}}
                 Arizona Health Plan, Inc.
                 Healthsource Properties, Inc.
       Managed Care Consultants, Inc.
       Choicelinx Corporation
        Sagamore Health Network, Inc.
Cigna Healthcare Holdings, Inc. (ET# 84-0985843)
       Great-West Healthcare of Illinois, Inc. (EI# 93-1174749, NAIC 95388, IL)
       Cigna Healthcare, Inc.
 *Cigna Life Insurance Company of New York (EI# 13-2556568, NAIC # 64548, NY)
 *Connecticut General Life Insurance Company (EI# 06-0303370, NAIC # 62308, CT)
        CG Mystic Center LLC
              Station Landing LLC
        CG Mystic Land LLC
              | ND/CG Holding LLC
        CG Skyline, LLC
               Skyline ND/CG LLC
                       ND Mystic Center Note LLC
                       Skyline Mezzanine Borrower, LLC
                              Skyline at Station Landing, LLC
        Careallies, LLC
        CG Bayport LLC
                Bayport Colony Apartments LLC
         Cigna Onsite Health, LLC
        Gillette Ridge Community Council, Inc.
        Gillette Ridge Golf LLC
        Hazard Center Investment Company LLC
        Tel-Drug of Pennsylvania, LLC
       GRG Acquisitions LLC
        Cigna Affiliates Realty Investment Group, LLC (EI# 27-5402196, DE)
               CR Longwood Investors, LP
                       ND/CR Longwood LLC
                              ARE/ND/CR Longwood LLC
               121 Tasman Apartments LLC
               Secon Properties, LP
               Transwestern Federal Holdings, L.L.C.
                       Transwestern Federal, L.L.C.
               Market Street Residential Holdings LLC
                       |Arborpoint at Market Street LLC
               Diamondview Tower CM-CG LLC
               CR Washington Street Investors LP
               Civic Holding LLC
               Dulles Town Center Mall, LLC
                AEW/FDG, LP
               ND/CR Unicorn LLC
               Union Wharf Apartments LLC
               AMD Apartments Limited Partnership
```

```
SP Newport Crossing LLC
                   PUR Arbors Apartments Venture LLC
                   CG Seventh Street, LLC
                   Ideal Properties II LLC
                   Alessandro Partners, LLC
                   Mallory Square Partners I, LLC
                   Houston Briar Forest Apartments Limited Partnership
                   Newtown Partners II, LP
                   Newtown Square GP LLC
                   AFA Apartments Limited Partnership
                   SB-SNH LLC
                            680 Investors LLC
                            |685 New Hampshire LLC
                   CGGL 18301 LLC
                   Unico/CG Commonwealth LLC
                            |Commonwealth Acquisition LLC
                   222 Main Street Caring GP LLC
                   222 Main Street Investors LP
                   Notch 8 Residential, L.L.C.
                   UVL, LLC
                  3601 North Fairfax Drive Associates, LLC
                  |CI Perris 151, LLC
                  |Lakehills CM - CG LLC
        |CORAC LLC
                   Bridgepoint Office Park Associates, LLC (EI# 27-3923999, DE)
                   Fairway Center Associates, LLC (EI# 27-3126102, DE)
                   Henry on the Park Associates, LLC (EI 27-3582688, DE)
         *Cigna Health and Life Insurance Company (EI # 59-1031071, NAIC # 67369, CT)
                   CarePlexus, LLC (EI# 45-2681649; DE)
                   Cigna Corporate Services, LLC (EI 27-3396038, DE)
                   Cigna Insurance Agency, LLC (EI # 27-1903785, CT)
                   Ceres Sales of Ohio, LLC (EI # 34-1970892, OH)
                   Central Reserve Life Insurance Company
(EI # 34-0970995, NAIC # 61727, OH)
                            |Provident American Life & Health Insurance Company (EI # 23-1335885, NAIC # 67903, OH)
                                      |United Benefit Life Insurance Company
(EI # 75-2305400, NAIC # 65269, OH)
                   Loyal American Life Insurance Company (EI # 63-0343428, NAIC # 65722, OH)
                               American Retirement Life Insurance Company I # 59-2760189, NAIC # 88366, OH)
                  QualCare Alliance Networks, Inc.
                            |
|QualCare, Inc.
|Scibal Associates, Inc.
|QualCare Captive Insurance Company Inc., PCC
|QualCare Management Resources Limited Liability Company
                            Health-Lynx,
                  |Sterling Life Insurance Company
|Olympic Health Management Sytesms, Inc.
|Olympic Health Management Services, Inc.
                  |WorldDoc, Inc.
Cigna Health Management, Inc.
(EI# 23-1728483, DE)
Kronos Optimal Health Company
(20-8064696, AZ)
*Life Insurance Company of North America
(EI# 23-1503749, NAIC # 65498, PA)
```

*Cigna & CMB Life Insurance Company Limited (remaining interest owned by an unaffiliated party) Cigna Direct Marketing Company, Inc. Tel-Drug, Inc. Vielife Holdings Limited Vielife Limited
Vielife Services, Inc.
Businesshealth UK Limited CG Individual Tax Benefit Payments, Inc. CG Life Pension Benefits Payments, Inc. CG LINA Pension Benefits Payments, Inc. Cigna Federal Benefits, Inc. Cigna Healthcare Benefits, Inc. Cigna Integratedcare, Inc. Cigna Managed Care Benefits Company Cigna Re Corporation | Blodget & Hazard Limited Cigna Resource Manager, Inc. Connecticut General Benefit Payments, Inc. Healthsource Benefits, Inc. IHN, Inc. LINA Benefit Payments, Inc. Mediversal, Inc. | Universal Claims Administration Cigna Global Holdings, Inc. Cigna International Corporation, Inc. Cigna International Services, Inc. Cigna International Marketing (Thailand) Limited CGO Participatos LTDA YCFM Servicos LTDA *Cigna Global Reinsurance Company, Ltd. Cigna Holdings Overseas, Inc. Cigna Bellevue Alpha LLC Cigna Linden Holdings, Inc. Cigna Laurel Holdings, Ltd. Cigna Palmetto Holdings, Ltd. |Cigna Apac Holdings Limited |Cigna Alder Holdings, LLC |Cigna Walnut Holdings, Ltd. Cigna Chestnut Holdings, Ltd. *LINA Life Insurance Company of Korea | Cigna Korea Foundation | Cigna International Services Australia Pty Ltd. Cigna Hong Kong Holdings Company Limited Cigna Data Services (Shanghai) Company Limited | Cigna HLA Technology Services Limited *Cigna Worldwide General Insurance Company Limited ${}^{\star}\underline{\text{Cigna Worldwide Life Insurance}} \ \underline{\text{Company Limited}}$ Cigna International Health Services Sdn Bhd. *Cigna Life Insurance New Zealand Limited *Cigna Life Insurance Company of Canada (AA-1560515) |Cigna Korea Chusik Heosa (A/K/A Cigna Korea Company Limited)
|LINA Financial Service RHP (Thailand) Limited *Cigna Brokerage & Marketing (Thailand) Limited |KDM (Thailand) Limited |*Cigna Insurance Public Company Limited 1 Cigna Taiwan Life Assurance Company Limited Cigna Myrtle Holdings, Ltd.

			Cigna Elmwood Holdings, SPRL
	1	1	Cigna Beechwood Holdings
			Cigna Life Insurance Company of Europe S.AN.V.
			Cigna Europe Insurance Company S.AN.V.
		ı	Cigna European Services (UK) Limited
	ı	I	Cigna 2000 UK Pension LTD
	1	1	Cigna Oak Holdings, LTD.
	1	1	Cigna Willow Holdings, LTD.
	ļ	ļ	FirstAssist Administration Limited
	1	I	<u>Cigna Legal Protection</u> Limited
Ltd.	1	I	<u>Cigna Insurance Services (Europe)</u>
	ı	I	
	I	I	Cigna International Health Services, LLC
	1	I	Cigna International Health Services Kenya Limited
			Cigna Sequoia Holdings, SPRL
	I	I	Cigna Magnolia Holdings, Ltd.
	1	I	Cigna Nederland Alpha Cooperatief U.A.
1	1	I	Cigna Nederland Beta B.V.
1	1	1	Cigna Nederland Gamma B.V.
	I	I	Cigna Finans Emeklilik Ve Hayat A.S.
	ļ	į.	Cigna Health Solution India Pvt. Ltd.
	I		
	1	1	religina lopial notatings, line.
			PT GAR Indonesia
			PT PGU Indonesia
			*Cigna Global Insurance Company Limited
			Cigna TTK Health Insurance Company Limited
			Cigna Saico Benefits Services W.L.L.
			*Cigna Worldwide Insurance Company (EI# 23-2088429, NAIC # 90859, DE)
			*PT. Asuransi Cigna
	1	Cigna	a Teak Holdings, LLC

OVERFLOW PAGE FOR WRITE-INS

Additional Write-ins for Underwriting and Investment Exhibit Part 3 Line 25

Additional Write-ins for Underwriting and investment Exhibit Part 3 Line 25									
	Claim Adjustment Expenses		3	4	5				
	1	2							
	Cost	Other Claim	General						
	Containment	Adjustment	Administrative	Investment					
	Expenses	Expenses	Expenses	Expenses	Total				
2504. Stipends - Provider			4,500		4,500				
2505. Claims Adjustment Expense - Other		354,380			354,380				
2597. Summary of remaining write-ins for Line 25 from		,			,				
overflow page	0	354,380	4,500	0	358,880				

ALPHABETICAL INDEX

ANNUAL STATEMENT BLANK

Analysis of Operations By Lines of Business	7
Assets	2
Cash Flow	
Exhibit 1 - Enrollment By Product Type for Health Business Only	
Exhibit 2 - Accident and Health Premiums Due and Unpaid	
Exhibit 3 - Health Care Receivables	
Exhibit 3A - Analysis of Health Care Receivables Collected and Accrued	
Exhibit 4 - Claims Unpaid and Incentive Pool, Withhold and Bonus	
Exhibit 6 - Amounts Due To Parent, Subsidiaries and Affiliates	
Exhibit 7 - Part 1 - Summary of Transactions With Providers	
Exhibit 7 - Part 2 - Summary of Transactions With Intermediaries	
Exhibit 8 - Furniture, Equipment and Supplies Owned	
Exhibit of Capital Gains (Losses)	
Exhibit of Net Investment Income	
Exhibit of Nonadmitted Assets	
Exhibit of Premiums, Enrollment and Utilization (State Page)	30
Five-Year Historical Data	29
General Interrogatories	27
Jurat Page	
Liabilities, Capital and Surplus	
Notes To Financial Statements	
Overflow Page For Write-ins	
Schedule A - Part 1	
Schedule A - Part 2	
Schedule A - Part 3	
Schedule A - Verification Between YearsSchedule B - Part 1	
Schedule B - Part 2	
Schedule B - Part 3	
Schedule B - Verification Between Years	
Schedule BA - Part 1	
Schedule BA - Part 2	
Schedule BA - Part 3	
Schedule BA - Verification Between Years	SI03
Schedule D - Part 1	
Schedule D - Part 1A - Section 1	SI05
Schedule D - Part 1A - Section 2	
Schedule D - Part 2 - Section 1	
Schedule D - Part 2 - Section 2	
Schedule D - Part 3	
Schedule D - Part 4	
Schedule D - Part 5	
Schedule D - Part 6 - Section 1Schedule D - Part 6 - Section 2	
Schedule D - Fait 6 - Section 2 Schedule D - Summary By Country	
Schedule D - Summary By Country Schedule D - Verification Between Years	
Schedule DA - Part 1	
Schedule DA - Verification Between Years	
Schedule DB - Part A - Section 1	
Schedule DB - Part A - Section 2	
Schedule DB - Part A - Verification Between Years	SI11
Schedule DB - Part B - Section 1	E20
Schedule DB - Part B - Section 2	E21
Schedule DB - Part B - Verification Between Years	
Schedule DB - Part C - Section 1	
Schedule DB - Part C - Section 2	
Schedule DB - Part D - Section 1	
Schedule DB - Part D - Section 2	
Schedule DB - Verification	
Schedule DL - Part 1	
Schedule DL - Part 2Schedule E - Part 1 - Cash	
Schedule E - Part 2 - Cash Equivalents	
Schedule E - Part 3 - Special Deposits	
Schedule E - Verification Between Years	

ANNUAL STATEMENT BLANK (Continued)

Schedule S - Part 1 - Section 2	31
Schedule S - Part 2	
Schedule S - Part 3 - Section 2	33
Schedule S - Part 4	34
Schedule S - Part 5	35
Schedule S - Part 6	36
Schedule S - Part 7	
Schedule T - Part 2 - Interstate Compact	
Schedule T - Premiums and Other Considerations	38
Schedule Y - Information Concerning Activities of Insurer Members of a Holding Company Group	40
Schedule Y - Part 1A - Detail of Insurance Holding Company System	41
Schedule Y - Part 2 - Summary of Insurer's Transactions With Any Affiliates	42
Statement of Revenue and Expenses	4
Summary Investment Schedule	SI01
Supplemental Exhibits and Schedules Interrogatories	43
Underwriting and Investment Exhibit - Part 1	
Underwriting and Investment Exhibit - Part 2	9
Underwriting and Investment Exhibit - Part 2A	10
Underwriting and Investment Exhibit - Part 2B	11
Underwriting and Investment Exhibit - Part 2C	12
Underwriting and Investment Exhibit - Part 2D	13
Underwriting and Investment Exhibit - Part 3	14